COMING SOON

ORLADEYO™
(berotralstat) capsules 150 mg

Visit our virtual booth at the ACAAI 2020 Annual Scientific Meeting.

Want to receive future updates on ORLADEYO™ (berotralstat)?

Sign up
American College of Allergy, Asthma & Immunology

Annual Scientific Meeting

The Changing Practice Landscape

RISING to the CHALLENGE

Nov. 13-15

VIRTUAL EXPERIENCE

2019 – 2020 Officers and Board of Regents

J. Allen Meadows, MD, FACAAI
President. .............................. 2020

Todd A. Mahr, MD, FACAAI
Immediate Past President. .............................. 2020

Luz S. Fonacier, MD, FACAAI
President-elect. .............................. 2020

Mark Corbett, MD, FACAAI
Vice President. .............................. 2020

Kathleen R. May, MD, FACAAI
Treasurer. .............................. 2020

Bradley E. Chipps, MD, FACAAI
Past Immediate Past President. .............................. 2020

Gailen D. Marshall, Jr., MD, PhD, FACAAI. .............................. 2020
Mamta Reddy, MD, MBOE, FACAAI. .................. 2020
Gary C. Steven, MD, PhD, FACAAI. .................. 2020
Kelly M. Maples, MD, FACAAI. .................. 2021
Melinda M. Rathkopf, MD, FACAAI. .................. 2021
Michael R. Rupp, MD, FACAAI. .................. 2021
Kevin R. Murphy, MD, FACAAI. .................. 2022
John Seyerle, MD, FACAAI. .................. 2022
J. Wesley Sublett, MD, MPH, FACAAI. .................. 2022

FIT Representatives: Miriam Samstein, MD, PhD (2020), and Timothy Chow, MD (2021)

Advocacy Council Chair: James M. Tracy, DO, FACAAI (2021)

Executive Medical Director: Michael S. Blaiss, MD, FACAAI

Annals Editor-in-chief: Gailen D. Marshall, Jr., MD, PhD, FACAAI (2021)

Alliance President: Cheryl Carr (2020)
ACAAM Premier Partners

The American College of Allergy, Asthma and Immunology recognizes the indispensable role that health care companies play in furthering the mission of the College. ACAAI would like to thank the following companies for their generous support of this year’s Annual Meeting.

**Diamond**
*$500,000 and above*
Sanofi Genzyme and Regeneron

**Platinum**
*$300,000 - $499,999*
AstraZeneca

**Gold**
*$100,000 - $299,999*
Aimmune Therapeutics
DBV Technologies
Genentech
GSK
Merck
Pfizer, Inc.
Takeda Pharmaceutical Company Limited

**Silver**
*$50,000 - $99,999*
abbvie
ALK
kaléo
Pharming Group NV
Teva Pharmaceuticals, Inc.

**Other Contributors**
Amgen • AstraZeneca and Amgen • BioCryst
Blueprint Medicines • CSL Behring • Fresenius Kabi USA, LLC
Novartis Pharmaceuticals Corporation • Optinose
Purina Institute • Stallergenes Greer
Table of Contents

ACAAI Premier Partners .......................... 4
2020 Program Committee .......................... 5
Message From the Program Chair ................. 7
2020 Award Winners ............................... 9
Corporate Supporters .............................. 11
Commercial Supporters ............................ 12
Special Announcements ........................... 15
SPARK Program .................................. 18
Education Information .............................. 19
Maintenance of Certification ........................ 21
Evaluation and Credit Claiming ..................... 22
Schedule at a Glance ............................... 23
Named Lectures ................................... 27
Friday, November 13 ............................... 28
Saturday, November 14 ............................ 37
Sunday, November 15 ............................. 50
E-posters ........................................ 63
Industry Programs .................................. 64
Exhibits .......................................... 71

2020 Program Committees

2020 Annual Meeting Program Committee

David R. Stukus, MD, Chair
Brian T. Kelly, MD, MA, Vice-chair
Michael S. Blaiss, MD • Mark L. Corbett, MD • Luz S. Fonacier, MD • Sandra M. Gawchik, DO
Matthew Greenhawt, MD, MBA, MSc • Jeremy S. Katcher, MD • Lisa J. Kobynski, MD, MPH
J. Allen Meadows, MD • Mervat Nassef, MD • Maeve E. O’Connor, MD • John J. Oppenheimer, MD
Purvi S. Parikh, MD • Melinda M. Rathkopf, MD • Melanie A. Ruffner, MD, PhD • Michael R. Rupp, MD
Jodi A. Shroba, MSN, APRN, CPNP • J. Wesley Sublett, MD, MPH • Miriam Samstein, MD, PhD, FIT Representative
Literature Review Liaison: David Khan, MD

2020 Allied Health Committee

Jodi A. Shroba, MSN, APRN, CPNP, Chair
Abby L. Allen, RN, NP, Vice-chair

Michelle R. Dickens, NP • Tara Doran, RN, BSN, MHA • Raquel Z. Durban, MS, RD, CSP, LDN
Maureen George, PhD, RN, AE-C • Tamara Hubbard, MA, LCPC • Ashlee Law, PA-C • Megan O. Lewis, MSN, RN, CPNP
Amanda L. Michaud, PA-C • Helen M. Murphy, RRT, AE-C • Ms. Iris Torres, RMA

2020 Practice Management Committee

Kevin P. McGrath, MD, Chair
Thomas J. Derrico, Vice-chair
Melinda M. Rathkopf, MD, Vice-chair

Stanley M. Fineman, MD, MBA • Charlie F. Furr, Jr. • Jennifer Kuehn, CPC • Alnoor A. Malick, MD
Scott McCutcheon, MHA • Mohsen Nasir, MD • Jean L. Owen, MBA, CT(ASCP) • M. Razi Rafeeq, MD
Paul A. Shapero, MD • Mike Tankersley, MD, MBA • John W. Tole, DO • James M. Tracy, DO • Kay Tyler, BS, BA, MBA
The Journey Towards Controlled Asthma: Shifting the Treatment Paradigm

Description: A goal of asthma treatment is to achieve and maintain asthma control; however, uncontrolled asthma continues to be a burden for patients, their care team, and the healthcare system. There is a need for providers and patients to share decision making while continuously evaluating treatment options that will maximize lung function, minimize symptoms and risk of exacerbations while decreasing the risk of adverse events. Medical experts will provide insight into the challenges of coping with uncontrolled asthma, review the current treatment paradigms, and identify ways to customize management of uncontrolled asthma by pairing the right medications with the right patients.

Speakers:
John Oppenheimer, MD
Angela Hogan, MD

Saturday, November 14, 2020
6:15 pm - 7:15 pm CST

An Industry Sponsored Program. Sponsored by GSK.

To access this industry program you must be registered for the virtual 2020 ACAAI Annual Scientific Meeting. All programs can be accessed via the main auditorium of the virtual meeting platform.

This program is limited to Health Care Professionals (HCP) only. Some state laws prohibit manufacturers from providing meals or transfers of value to HCPs. GSK complies with all state and federal laws including transparent reporting and disclosure of payments and transfers of value to HCPs. This is a non-CME event and does not qualify for CME, CE, or MOC credit. This event is not part of the official conference sessions.

The Industry Program content and views expressed therein do not necessarily reflect the views, policies or position of the American College of Allergy, Asthma and Immunology.
On behalf of the Program Committee, welcome to the College’s 2020 virtual Annual Meeting. When I walked out of our “final” planning meeting in late February, I had no idea the extent to which our world was about to change. Alas, we were fortunate to have time to regroup and we are very proud to be able to bring you a meeting filled with outstanding education, research and networking. We’ll give you the practical takeaways you need to care for patients and advance your practice, no matter your career stage or clinical setting.

Our session topics live up to this year’s theme, the Changing Practice Landscape – Rising to the Challenge (our theme was actually chosen 18 months ago...who knew?). Here are some highlights so you can maximize your experience:

- **Expert tips at the Presidential Plenary.** We’re excited to have Mr. Harold Miller, President and CEO of the Center for Healthcare Quality and Payment Reform, presenting “Why ‘Value-based Payment’ Isn’t Working – And How Physicians Can Fix It” during the Presidential Plenary on Friday at 8:00 am CST.

- **New, Friday LIVE sessions.** Don’t miss Friday afternoon’s sessions on COVID-19 and disparities. These were developed to specifically address timely topics important to all of us.

- **“Not on Thursday” program.** Two topics are covered in depth: cough and biologics. Learn about testing, diagnosis and treatment of cough and optimizing biologics for allergic conditions. These sessions take place on Saturday.

- **Tune in to your favorites.** Plan to attend favorites like the Annual Literature Review, CAP Review and oral abstract sessions. Nonmember attendees must preregister for the Literature Review.

- **Research? We’ve got it virtually.** View e-posters at your convenience. They are available on demand starting Friday at 9:30 am CST. We’ve added a new feature this year, and e-posters will be accompanied by recorded author presentations!

- **Don’t miss the FIT Bowl!** You didn’t think we were going to let the Fellows-in-Training off the hook, did you? An Annual Meeting tradition, join us for a virtual spin on this knowledge competition for FIT teams on Saturday at 5:15 pm CST.

- **Yes, there will be an exhibit hall!** No meeting would be complete without our industry partners. You’ll be able to chat with industry representatives and view their interactive exhibits starting on Friday at 9:30 am CST. Don’t forget to collect your tokens at participating booths to be eligible to win prizes!

- **Visit the College booth in the virtual exhibit hall** to see how the College is working for you. We’ll be on hand during exhibit hours to greet you and answer your College questions.

- **Virtual social experiences round out the meeting.** In addition to the FIT Bowl, visit the Networking Lounge to connect with peers.

Keep the momentum going during the meeting! Tweet the best pearls and tips you’re learning from each session, and use #ACAAI20 in your tweets. Follow Facebook and Twitter for breaking Annual Meeting news.

I hope you enjoy the one-of-a-kind experience at this year’s virtual Annual Meeting. We’re looking forward to hopefully meeting in person next year in New Orleans. Please feel free to give us feedback during and after the meeting via the evaluations or at the help desk. I assure you that your comments are extremely important to us as we plan future meetings. While we can’t be together in person, we can still be together throughout this wonderful weekend.
Investigating the Role of Eosinophils in Health, Airway Disease, and Hypereosinophilic Disorders

Program Description: Eosinophils are now well recognized as major players in immune-mediated disorders. This program will review the immunomodulatory role of eosinophils in health and disease as well as their involvement in various disorders, including severe asthma (and potential co-morbidities) and hypereosinophilic disorders. The importance of biomarkers in the evaluation of eosinophilic disorders will be highlighted.

Current Understanding of Hypereosinophilic Syndrome (HES): A Rare Inflammatory Eosinophilic Disease

Program Description: Hypereosinophilic syndrome (HES) is a rare and debilitating multi-system disorder characterized by elevated eosinophil levels in blood and/or tissues with organ damage/dysfunction that occurs without evidence of secondary causes of hypereosinophilia. Multiple organ involvement results in highly variable clinical manifestations. This brief presentation will provide a summary of current understanding.

An Industry Sponsored Program. Sponsored by GSK.

To access this industry program you must be registered for the virtual 2020 ACAAI Annual Scientific Meeting. All programs can be accessed via the main auditorium of the virtual meeting platform.

This program is limited to Health Care Professionals (HCP) only. Some state laws prohibit manufacturers from providing meals or transfers of value to HCPs. GSK complies with all state and federal laws including transparent reporting and disclosure of payments and transfers of value to HCPs. This is a non-CME event and does not qualify for CME, CE, or MOC credit. This event is not part of the official conference sessions.

The Industry Program Content and views expressed therein do not necessarily reflect the views, policies, or position of the American College of Allergy, Asthma and Immunology.

Trademarks are owned by or licensed to the GSK group of companies.

©2020 GSK group of companies or its licensor.

August 2020 Produced in USA. MA-EOSINO-ACAAI-ISP-3
The College is proud to honor the following individuals for their service to the College and the specialty of allergy/immunology. All awards will be presented during the ACAAI Business Meeting at 4:30 pm CST on Saturday.

**GOLD HEADED CANE AWARD**

Stanley M. Fineman, MD, MBA, FACAAI  
Marietta, Georgia

**Distinguished Fellow Award**

Michael R. Nelson, MD, PhD, FACAAI  
Olney, Maryland

**Distinguished Service Awards**

Travis A. Miller, MD, FACAAI  
Roseville, California

James M. Tracy, DO, FACAAI  
Papillion, Nebraska

Susan L. Grupe  
ACAAI Director of Advocacy Administration  
Barrington, Illinois

**International Distinguished Fellow Award**

Michael Levin, MD, PhD, FACAAI  
Rondebosch, South Africa

**Woman in Allergy Award**

Mariana C. Castells, MD, PhD, FACAAI  
Boston, Massachusetts

**Executive Medical Director Award**

Jennifer Pfeifer, MBA, CMPE  
ACAAI Practice Management Manager  
Northbrook, Illinois

**Clemens von Pirquet Awards**

**First Place**  
Jose Rojas Camayo, MD  
University of Texas Medical Branch

**Second Place**  
Lily Li, MD  
Brigham and Women’s Hospital

**Third Place**  
Deepti Deshpande, MD  
Columbia University
THIS IS REAL LIFE.

See for yourself at RealLifeNUCALA.com

Real patient compensated by GSK for his time.

Trademarks owned or licensed by GSK.
©2020 GSK or licensor.
MPLJRRA2000007 September 2020
Produced in USA.

NUCALA Autoinjector

See for yourself at RealLifeNUCALA.com
ACAAI appreciates the following promotional contributions from its corporate supporters.

**abbvie**  
Supporter of the ACAAI Corporate Council.

**Aimmune Therapeutics**  
Supporter of the ACAAI Corporate Council...banner advertisement in the Help Desk...and an Industry Program presentation.

**ALK**  
Supporter of the ACAAI Corporate Council...Find an Allergist widget...and a non-CME webinar on “Operationalize Penicillin Allergy Testing.”

**Amgen**  
Supporter of the ACAAI Corporate Council.

**AstraZeneca and Amgen**  
Supporter of an Industry Program presentation.

**AstraZeneca**  
Supporter of the ACAAI Corporate Council...the Leadership Summit...Allergy & Asthma Awareness Toolkit...National Asthma & Allergy Awareness Month Toolkit...a non-CME webinar on “Asthma and Racial Disparities – How Can Allergists Improve Outcomes”...three Industry Program presentations...Twitter content...banner advertisements in the Lobby...three broadcast messages...and two pre-meeting email banner advertisements.

**BioCryst**  
Supporter of an advertisement in the final program guide...Networking Lounge...banner advertisement in the Help Desk...and a pre-meeting email banner advertisement.

**Blueprint Medicines**  
Supporter of an Industry Program presentation.

**DBV Technologies**  
Supporter of the ACAAI Corporate Council ...FIT Bowl...and an Industry Program presentation.

**Fresenius Kabi USA, LLC**  
Supporter of a non-CME webinar on “HAE - Looking Into the Future”...and a broadcast message.

**Genentech**  
Supporter of the ACAAI Corporate Council.

**GSK**  
Supporter of the ACAAI Corporate Council...two slide decks on “The Burden of Uncontrolled Asthma and the Role of LAMA in the Treatment of Asthma”...four Industry Programs presentations...Twitter content...two broadcast messages...banner advertisement in the Help Desk...and three advertisements in the final program guide.

**kaléo**  
Supporter of the ACAAI Corporate Council...College Insider...and an Industry Program presentation.

**Merck**  
Supporter of a Podcast Series on “Cough.”

**Novartis Pharmaceuticals Corporation**  
Supporter of the ACAAI Corporate Council...and an Industry Program presentation.

**Optinose**  
Supporter of the ACAAI Corporate Council.

**Pfizer, Inc.**  
Supporter of the ACAAI Corporate Council...“Reducing Disparities in Atopic Dermatitis Education” Campaign...two Industry Program presentations...two broadcast messages...and a banner advertisement in the Resource Center.

**Pharming Group NV**  
Supporter of the ACAAI Corporate Council...and a banner advertisement in the Lobby.

*Continues next page*
This activity is supported by independent educational grants from the following commercial supporters:

**Aimmune Therapeutics**
Supporter of the Allied Health Professionals Course.

**Astrazeneca**
Partial supporter of the Sunday Symposium on “Caring for Patients Across Populations.”

**CSL Behring**
Partial supporter of the Friday Symposium on “Everything You Wanted to Know About IgG Replacement, But Didn’t Know You Needed to Ask.”

**Genentech**
Supporter of the Friday Symposium on “Approach to Diagnosis and Management of Nasal Polyps in the Biologic Era.”

**Merck**
Supporter of the Saturday “Not on Thursday Program: Cough.”

**Stallergenes Greer**
Supporter of the ACAAI Corporate Council.

**Takeda Pharmaceutical Company Limited**
Supporter of the ACAAI Corporate Council...two Industry Program presentations...Twitter content...banner advertisements in the Lobby and Resource Center...three pre-meeting email banner advertisements...and three broadcast messages.

**Teva Pharmaceuticals, Inc.**
Supporter of an Industry Program presentation...and a non-CME webinar on “The Past, Present and Future of Asthma Monitoring Devices.”

**Purina Institute**
Supporter of an Industry Program presentation.

**Sanofi Genzyme and Regeneron**
Supporter of the ACAAI Corporate Council...three Industry Program presentations...Annual Meeting daily e-newsletter...e-posters...Twitter content...pre-meeting email banner advertisement...Find an Allergist locator...AllergyWatch...the ACAAI Racial Disparities Resource Center...non-CME webinar on “Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)”...CRSwNP Educational Tool for Allergists Patient Education Guide...CRSwNP Shared Decision-making Toolkit...CRSwNP Patient Success Video and Digital Ad Campaign...Severe Asthma Patient Success Video and Digital Ad Campaign...Atopic Dermatitis Patient Success Video and Digital Ad Campaign...Asthma page on ACAAI website...Eczema page on ACAAI website...Adult Asthma Shared Decision-Making Online Tool Redesign...Practice Management Resource Video...Practice Management Programs: Expansion and Enhancement...Practice Assessment Quiz...non-CME webinar on “Telemedicine and COVID-19: Getting Started”...COVID-19 Resource Center...and partial support of the non-CME webinar on “Managing Your Asthma Patients During COVID-19.”

**Commercial Supporters (continued)**

**Stallergenes Greer**
Supporter of the ACAAI Corporate Council.

**Takeda Pharmaceutical Company Limited**
Supporter of the ACAAI Corporate Council...two Industry Program presentations...Twitter content...banner advertisements in the Lobby and Resource Center...three pre-meeting email banner advertisements...and three broadcast messages.

**Teva Pharmaceuticals, Inc.**
Supporter of an Industry Program presentation...and a non-CME webinar on “The Past, Present and Future of Asthma Monitoring Devices.”

**Purina Institute**
Supporter of an Industry Program presentation.

**Sanofi Genzyme and Regeneron**
Supporter of the ACAAI Corporate Council...three Industry Program presentations...Annual Meeting daily e-newsletter...e-posters...Twitter content...pre-meeting email banner advertisement...Find an Allergist locator...AllergyWatch...the ACAAI Racial Disparities Resource Center...non-CME webinar on “Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)”...CRSwNP Educational Tool for Allergists Patient Education Guide...CRSwNP Shared Decision-making Toolkit...CRSwNP Patient Success Video and Digital Ad Campaign...Severe Asthma Patient Success Video and Digital Ad Campaign...Atopic Dermatitis Patient Success Video and Digital Ad Campaign...Asthma page on ACAAI website...Eczema page on ACAAI website...Adult Asthma Shared Decision-Making Online Tool Redesign...Practice Management Resource Video...Practice Management Programs: Expansion and Enhancement...Practice Assessment Quiz...non-CME webinar on “Telemedicine and COVID-19: Getting Started”...COVID-19 Resource Center...and partial support of the non-CME webinar on “Managing Your Asthma Patients During COVID-19.”

**Commercial Supporters (continued)**
The ACAAI FIT Bowl – now in its 29th consecutive year - is patterned after a popular TV quiz show. This year, 19 teams competed in preliminary rounds and 4 will complete for the coveted FIT Bowl trophy. The teams will test their knowledge, cleverness and ability to listen and quickly respond to questions in this fast-paced event.

The questions have been developed by a variety of sources and encompass a wide range of topics including all aspects of allergy/immunology and the history of our profession.

The evening is designed to be fun, light-hearted and educational. The first FIT Bowl was conceived by the late Dr. John Selner (ACAAI President 1992-93), and introduced at the College’s 50th Anniversary meeting. Dr. Selner turned to Dr. Kevin Murphy to bring his idea to life and Drs. Bryan Martin and Kevin Murphy have co-chaired the FIT Bowl ever since.

The emcee for this year’s program will be Dr. Bryan Martin.

<table>
<thead>
<tr>
<th>FINAL ROUND</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEAM 1</td>
</tr>
<tr>
<td>TEAM 3</td>
</tr>
<tr>
<td>Drs. Venkatesh Sabhae-Gangadharappa and Alexander Babazadeh&lt;br&gt;SUNY Downstate Medical Center</td>
</tr>
</tbody>
</table>

Continues next page
## FIT Bowl Winning Teams

<table>
<thead>
<tr>
<th>YEAR</th>
<th>FIRST PLACE</th>
<th>TEAM MEMBERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>Wilford Hall Ambulatory Surgical Center</td>
<td>Drs. Brittanie Neaves and Geoffrey Carlson</td>
</tr>
<tr>
<td>2018</td>
<td>University of Tennessee and Wilford Hall</td>
<td>Drs. Anita Sivam and Brittanie I. Neaves</td>
</tr>
<tr>
<td>2017</td>
<td>Mayo Clinic</td>
<td>Drs. Joshua M. Dorn and Caitlin McNulty</td>
</tr>
<tr>
<td>2016</td>
<td>Children’s Mercy Hospitals &amp; Clinics</td>
<td>Drs. Brooke Polk and Hani Hadi</td>
</tr>
<tr>
<td>2015</td>
<td>Wilford Hall Medical Center</td>
<td>Drs. Derek Smith and Katherine Tille</td>
</tr>
<tr>
<td>2014</td>
<td>Wilford Hall Medical Center</td>
<td>Drs. Derek Smith and Priscilla Wong</td>
</tr>
<tr>
<td>2013</td>
<td>University of Texas Southwestern Medical Center</td>
<td>Drs. Merin Kuruvilla and Sharon Deol</td>
</tr>
<tr>
<td>2012</td>
<td>Wilford Hall Medical Center</td>
<td>Drs. Scott Dickson and David Rose</td>
</tr>
<tr>
<td>2011</td>
<td>Wilford Hall Medical Center</td>
<td>Drs. Shayne Stokes and Jeremy Sikora</td>
</tr>
<tr>
<td>2010</td>
<td>Wilford Hall Medical Center</td>
<td>Drs. Monica Johnson and Mark Stahl</td>
</tr>
<tr>
<td>2009</td>
<td>Duke University Medical Center</td>
<td>Drs. Pooja Varshney and Rafael Firszt</td>
</tr>
<tr>
<td>2008</td>
<td>Medical College of Wisconsin</td>
<td>Drs. Anita Gheller-Rigoni and Amit Kumar</td>
</tr>
<tr>
<td>2007</td>
<td>Medical College of Wisconsin</td>
<td>Drs. Titus Chang and Monica Vasudev</td>
</tr>
<tr>
<td>2006</td>
<td>Wilford Hall Medical Center</td>
<td>Drs. Christopher Calabria and Stephen E. Scranton</td>
</tr>
<tr>
<td>2005</td>
<td>Medical College of Georgia</td>
<td>Drs. Cristina M. Mazzoni and Jason R. Perry</td>
</tr>
<tr>
<td>2004</td>
<td>Wilford Hall Medical Center</td>
<td>Drs. Rajiv Arora and Eric Meier</td>
</tr>
<tr>
<td>2003</td>
<td>Cleveland Clinic</td>
<td>Drs. Todd Rambasek and Hary Katz</td>
</tr>
<tr>
<td>2002</td>
<td>Wilford Hall Medical Center</td>
<td>Drs. Daniel R. Moore and Ronald W. England</td>
</tr>
<tr>
<td>2001</td>
<td>Medical College of Georgia</td>
<td>Drs. William A. McCann and Reid F. Johnstone</td>
</tr>
<tr>
<td>2000</td>
<td>Wilford Hall Medical Center</td>
<td>Drs. William T. Bolesan and Diane C. Napoli</td>
</tr>
<tr>
<td>1999</td>
<td>Medical College of Georgia</td>
<td>Drs. Marc Cromie and Andrea Lantz</td>
</tr>
<tr>
<td>1998</td>
<td>Medical College of Georgia</td>
<td>Drs. Marc Cromie and Jack L. Armstrong</td>
</tr>
<tr>
<td>1997</td>
<td>Wilford Hall Medical Center</td>
<td>Drs. Joshua S. Jacobs and Russel Walker</td>
</tr>
<tr>
<td>1996</td>
<td>Wilford Hall Medical Center</td>
<td>Drs. Joshua S. Jacobs and Larry L. Hagan</td>
</tr>
<tr>
<td>1995</td>
<td>Wilford Hall Medical Center</td>
<td>Drs. Larry Hagan and Christine Schafer</td>
</tr>
<tr>
<td>1993</td>
<td>Wilford Hall Medical Center – Air Force Fellowship</td>
<td>Drs. William Butler and James Quinn</td>
</tr>
<tr>
<td>1992</td>
<td>The Long Island Jewish Hospital</td>
<td>Drs. Steven Smith and David Wertheim</td>
</tr>
</tbody>
</table>

Drs. Brittanie Neaves and Geoffrey Carlson of Wilford Hall proudly show the 1st place trophy won at the 28th Annual FIT Bowl last year.
Annual Meeting Website
Maximize your time at the meeting! Find schedules, download handouts and access all the information you need at annualmeeting.acaai.org.

Dates and Times
The virtual meeting program will be held on the following dates. All sessions are listed in Central Standard Time (CST).

**Friday, November 13** . . . . . . 7:30 am – 6:30 pm CST
**Saturday, November 14** . . . . 7:00 am – 7:15 pm CST
**Sunday, November 15** . . . . . 7:00 am – 4:30 pm CST

E-posters
E-posters go live at 9:30 am CST on Friday, November 13 and are accessible on demand 24/7. Search for specific topics or browse at your leisure.

**New for 2020:** E-posters will be accompanied by an audio/visual presentation delivered by the presenting author.

E-posters will remain viewable on demand for 6 months following the Annual Meeting at college.acaai.org/eposters.

Supported by Sanofi Genzyme and Regeneron

Capturing of NPI Numbers
As part of the health care reform legislation signed into law in March 2010, the Physician Payment Sunshine Act requires medical device, biologic and drug companies to publicly disclose gifts and payments made to physicians.

To help our ACAAI Annual Scientific Meeting exhibitors and industry partners in fulfilling the mandatory reporting provisions of the Sunshine Act, the College is requesting U.S. health care provider attendees supply their 10-digit NPI (National Provider Identifier) number when registering for the Annual Scientific Meeting. The NPI number will be made available to exhibitors in their final lead retrieval report they receive at the end of the meeting so that they can record and track any reportable transactions.

College Booth
Visit the College booth in the virtual exhibit hall to learn about valuable member resources available online on the College website, in the College Learning Connection and the Practice Management Center. Sign on to a letter to policymakers in support of our advocacy for allergists and patients.

Credit Claiming
For your convenience, the College uses an online evaluation and credit claiming system. This system allows you to complete evaluations and claim credit for sessions attended. After completing an annual meeting evaluation, you will be able to save and/or print your certificate. Complete details can be found on page 22.

Disclaimer
The primary purpose of the ACAAI Annual Scientific Meeting is educational. Information, as well as technologies, products and/or services discussed, is intended to inform participants about the knowledge, techniques and experiences of specialists who are willing to share such information with colleagues. A diversity of professional opinions exists in the specialty and the views of the College disclaim any and all liability for damages to any individual attending this conference and for all claims which may result from the use of information, technologies, products and/or services discussed at the conference.

Foundation
The College’s Foundation, now named the Allergists’ Foundation, has taken a new direction in its programming to focus more keenly on the needs of practicing community allergists. Stop by the Foundation booth in the virtual exhibit hall to learn more and get information on how you can apply for a grant and/or support these efforts.
Handouts
Session handouts are available for download in the virtual meeting Resource Center or at annualmeeting.acaai.org/handouts. Handouts for live sessions will also be available for download when you enter the session.

Industry Programs
These non-CME commercial presentations and promotional sessions are organized by industry and designed to enhance your meeting experience. All attendees are invited to attend these sessions, which are scheduled at the start and end of each day and during break times between educational sessions. Industry programs will remain viewable on demand through February 6, 2021 following the Annual Meeting.

Leaderboard Competition
Throughout the meeting, attendees can collect points to qualify for valuable prizes. After logging in to the virtual meeting platform, click on the trophy icon on the upper right corner of your screen to display the leaderboard. You’ll automatically earn tokens and points by visiting various booths in the exhibit hall and participating in other meeting activities. Check the leaderboard throughout the weekend to see who’s winning!

Gift cards will be awarded to top scorers. All players with scores over a certain threshold (other than top score winners) will be entered into a raffle for additional prizes. All tokens/points must be collected by 5:00 pm CST on Sunday, November 15. Complete contest rules will be posted on the Annual Meeting website.

Meeting on Demand
The recorded educational sessions from the 2020 Annual Meeting will be hosted on the College Learning Connection in early December. We provide a variety of online packages designed to meet your particular needs, from the entire set of recordings to topical collections. Go to education.acaai.org/ondemand.

MOC Designated Sessions
Due to the virtual format of this year’s Annual Meeting, ACAAI will not be designating any 2020 Annual Meeting sessions for MOC Part II Self-Assessment Credit. However, you’ll find other opportunities to earn MOC Part II self-assessment credit on the College Learning Connection (education.acaai.org).

Networking Goes Viral: #ACAAI20
Check out the networking lounge and be a part of the Annual Meeting conversation! Use #ACAAI20 in your meeting-related tweets and follow the College @ACAAI. Also, share Facebook posts from facebook.com/TheACAAI.

Oral Abstracts
The ACAAI Abstract Review Committee has selected only the most dynamic and relevant research submissions to share with our Attendees during the 2020 Annual Meeting. More than 35 abstract authors will deliver cutting-edge research presentations and answer your questions during online chats.

Photography/Video Recordings
By registering for this meeting, attendees acknowledge and agree that ACAAI or its agents may take photographs or screen shots during events and may freely use those images in any media for College purposes, including, but not limited to, news and promotional purposes.

The presentations, slides and materials provided in this program are the property of the College or are used with permission of the owner. You may not photograph, videotape, audiotape or otherwise record or reproduce any of the presentations without express written permission from the College. Please note that a single screen shot may accompany a social media post about a presentation.
Registration
The virtual meeting is accessible only to registered attendees.

REGISTRATION DEADLINE: NOVEMBER 9, 2020

Registration includes:
• Access to all live and prerecorded sessions until February 6, 2021.
• Access to the Annual Literature Review Course.*
• Access to the Allied Health and Practice Management Courses.**
• Access to cutting-edge research through abstracts and e-posters.
• Access to the virtual exhibit hall until February 6, 2021.
• Virtual networking and social opportunities during the event.

*In order to attend the full-day Annual Literature Review Course, you must select it on the Optional Workshops page when you register. ($75 additional fee for nonmembers, international affiliate members and Alliance members.)

**In order to be eligible for educational credit for the Allied Health Professionals Course and the Advanced Practice Health Care Providers Course, you must select these on the Optional Workshops page when you register.

Session Types

LIVE
Join these sessions at the posted start times to view the live presentations and participate in the online discussion. Can’t attend at the designated time? Live sessions will be recorded and posted for viewing within 12 hours.

RECORDED+
Tune in to these sessions during their scheduled time to join in the online chat with session faculty.

RECORDED
Watch and join these prerecorded sessions as they become available throughout the day, or view them anytime afterward at your leisure.

Special Needs
In compliance with the Americans with Disabilities Act, ACAAI requests that participants in need of special accommodation submit a written request to ACAAI well in advance.

Tracks
To make it easier for participants to identify Annual Meeting sessions that are relevant to their practice, the College has identified nine critical areas for allergy and immunology. These nine areas make up the Annual Meeting Track System.

Virtual Exhibit Hall
The virtual exhibit hall opens at 9:30 am CST on Friday, November 13. The College appreciates the support of its exhibitors and urges all attendees to visit over 40 virtual booths in the exhibit hall. Chat with industry representatives during meeting hours, or drop in anytime to view exhibits. Plus, collect tokens for the Leaderboard Contest to qualify to win great prizes!

Also visit the College and Foundation booths to learn about resources and opportunities to engage.

Exhibits will remain viewable through February 6, 2021.
SPARK Program

The ACAAI SPARK program was developed to help “spark” an interest in residents who might be considering a career in allergy-immunology. This year’s SPARK program provides an opportunity for residents (Pediatric, Internal Medicine, and Med-Peds) to attend this year’s virtual ACAAI Meeting. Awardees will participate in a special Fellows-in-Training (FIT) symposium and attend a wide variety of sessions covering all aspects of allergy-immunology. With the leadership of the Program Directors Committee chaired by Tracy Fausnight, MD, and FIT Representatives, Miriam Samstein, MD, PhD, and Timothy Chow, MD, each SPARK recipient will have a FIT mentor while attending the meeting and beyond.

Catalina Acosta Orozco, MD • Woodhull Medical Center
Eosa Adah, MD • Children’s Mercy
O. Ann Adesuayi, MD • Indiana University School of Medicine-Pediatric Residency Program
Ruizhi Dong, MD • Ohio State University Wexner Medical Center Internal Medicine Residency Primary Care Track
Harris Richard Droghini, MD • Cincinnati Children’s Hospital
Charlene M. Dunaway Altamirano, PhD • Cleveland Clinic Internal Medicine Residency Program
Rebecca Duron, MD • University of Texas Southwestern Medical Center
Daniel Hamilton, MD • University of Buffalo Pediatric Residency Program
Ari Heffes-Doon, MD • NYU Langone Health, NYU Winthrop Hospital
Derek MacMath, MD • Baylor Internal Medicine-Pediatrics
Martin Maldonado-Puebla, MD • George Washington University Internal Medicine
Minh Nguyen, DO • Western Michigan University School of Medicine
Priya K. Patel, MD • John Hopkins All Children’s Hospital
Shipra Rai, MD • General Pediatrics at Cohen Children’s Medical Center
Irene Yuan, MD • University of California, Los Angeles
This activity is supported by independent educational grants from:

- Aimmune Therapeutics
- AstraZeneca
- CSL Behring
- Genentech
- Merck

Target Audience
Medical professionals who treat patients with allergic and/or immunological conditions:

- Practicing allergist/immunologists
- Allergy/immunology Fellows-in-Training
- Physician assistants
- Advanced practice nurses
- Allied health professionals
- Primary care physicians
- Other medical professionals

Overall Educational Objectives
At the conclusion of this activity, participants should be able to:

- Identify major advances in key areas of cutting-edge research in immunologic mechanisms and allergic responses, including anaphylaxis and pathophysiology of the upper airways, lungs, eyes, skin and gastrointestinal tract.
- Demonstrate knowledge of basic processes linking molecular and cellular biology and genetics with allergic pathophysiology and immunodeficiency.
- Translate emerging clinical science principles to clinical practice in patients with allergic and immunologic diseases.
- Evaluate and implement state-of-the-art diagnostic and therapeutic strategies for treating patients with allergic and immunologic diseases.
- Explain the impact of environmental exposures and external influences on patients with allergic disorders.
- Recognize emerging trends in the prevalence of allergic and immunologic disorders and discuss their impact on public health.
- Evaluate the impact of new diagnostic and therapeutic strategies on health care costs and outcomes.
- Discuss processes, tools and technologies for the efficient allergy and immunology practice.
Disclosure Statement

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, the College must identify and resolve conflicts of interest for all individuals responsible for the development, management, presentation, and/or evaluation relevant to a CME activity. Disclosed information is reviewed in advance in order to manage and resolve any potential conflicts of interest. Disclosure in no way implies that the information presented is biased or of lesser quality; it is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations.

Specific disclosure information for the 2020 Annual Meeting is conveniently located on the Annual Meeting website at college.acaai.org/disclosures.

Accreditation Statements

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 31.5 contact hours.

Credit Designation

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 31.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The continuing medical education activity has been reviewed by the American Academy of Pediatrics (AAP) and is acceptable for a maximum of 31.5 AAP credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the AAP.

Advanced Practice Health Care Providers Course:
This activity has been designated for up to 4.75 Continuing Education contact hours.

Allied Health Professionals Course:
This activity has been designated for up to 6.75 Continuing Education contact hours.

The virtual meeting is considered a live activity scheduled for the dates of November 13 – 15. In order to earn credit, you must log into the meeting during those dates. Credit claimed should be commensurate with your participation during that period.
Due to the virtual format of this year’s Annual Meeting, ACAAI will not be designating any 2020 Annual Meeting sessions for MOC Part II Self-Assessment Credit. However, you’ll find other opportunities to earn MOC Part II self-assessment credit at the College Learning Connection (education.acaai.org).

The American Board of Allergy and Immunology’s (ABAI) Maintenance of Certification (MOC) program facilitates a physician’s commitment to lifelong learning. Part II of ABAI’s MOC program requires that diplomates obtain 25 CME credits in the areas of allergy and/or immunology on an annual basis. The CME credits for the Annual Meeting can be used to satisfy this requirement. In addition to the required 25 CME credits, the ABAI recommends that six of the CME credits also qualify as Self-Assessment credit (aka MOC Part II credit).

ACAAI seamlessly transfers your Annual Meeting CME and MOC Part II credits to the ABAI at the end of the calendar year.

Please note that faculty cannot earn CME or MOC Part II credit for their presentations.

Core Competencies
ACAAI is committed to providing educational activities that align with the ABAI Core Competencies, which include:

• Patient Care and Procedural Skills
• Medical Knowledge
• Practice-based Learning and Improvement
• Interpersonal and Communication Skills
• Professionalism
• Systems-based Practice

Disclaimer
The primary purpose of the ACAAI Annual Scientific Meeting is educational. Information, as well as technologies, products and/or services discussed, is intended to inform participants about the knowledge, techniques and experiences of specialists who are willing to share such information with colleagues. A diversity of professional opinions exists in the specialty and the views of the College disclaim any and all liability for damages to any individual attending this conference and for all claims which may result from the use of information, technologies, products and/or services discussed at the conference.
Evaluation and Credit Claiming

This year’s virtual meeting is considered a “live” event for credit purposes. That means credit can only be claimed if you are logged into the meeting during November 13-15. Credit is calculated at daily maximum of 10.5 credits, for a 3-day maximum of 31.5 credits. For your convenience, the College uses an online evaluation and credit claiming system for the 2020 Annual Scientific Meeting. This system allows you to complete evaluations and claim credit for sessions attended. After completing an overall meeting evaluation, you will be able to save and/or print your certificate. You may complete your evaluations and claim credit anytime between the meeting and the end of this year; however, we strongly urge you do this sooner rather than later!

How to log into the evaluation and credit claiming system:

1) Go to annualmeeting.acaai.org.
2) Click the “Claim Credit” button.
3) Log in using your last name and ACAAI ID number.
4) Complete the evaluations and claim your credit for the sessions you attended.
5) Complete the overall meeting evaluation.
6) Save and/or print your certificate.

Please complete the evaluation and credit claiming by December 31, 2020.

Certificates:

- CME Certificates will be awarded to physicians only, per the American Medical Association (AMA PRA Handbook, p. 8).
- Certificates of Attendance will be awarded to any non-physician participants who complete the evaluation and credit claiming.
- CBRN credit certificates will be awarded to nurses and nurse practitioners.

Visit annualmeeting.acaai.org for additional information.

Replacement Certificates:

Once you have claimed credit for the 2020 Annual Meeting, your certificate will always be available on the College Learning Connection (education.acaai.org). Log in using your College username/password, and click “My Account,” then “My Learning” to find your learning transcript.
## Schedule at a Glance

*All sessions are listed in Central Standard Time (CST).*

### Friday, November 13

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 – 8:00 am CST</td>
<td><strong>Opening Ceremony and Welcome Announcements</strong></td>
</tr>
<tr>
<td>8:00 – 9:30 am CST</td>
<td><strong>Presidential Plenary: The Changing Payment System - Challenge Accepted!</strong></td>
</tr>
<tr>
<td>9:30 am CST</td>
<td>Virtual Exhibit Hall Opens</td>
</tr>
<tr>
<td></td>
<td>E-posters Open</td>
</tr>
<tr>
<td>9:35 – 10:00 am CST</td>
<td><strong>Non-CME Industry Program:</strong> Type 2 Inflammation in Asthma</td>
</tr>
<tr>
<td>10:00 – 11:30 am CST</td>
<td><strong>Guiding Patients Through Peanut Immunotherapy Options</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Approach to Diagnosis and Management of Nasal Polyps in the Biologic Era</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Everything You Wanted To Know About IgG Replacement, but Didn’t Know You Needed To Ask</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Joint ACAAI/AAP-SOA Session - 7 for 11: Hot Topics in Pediatric A/I</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Practice Management in a Changing Landscape - Billing and Coding Update</strong></td>
</tr>
<tr>
<td>11:35 am – 12:30 pm CST</td>
<td><strong>Non-CME Industry Programs:</strong> PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] From Evidence to Practice: The First FDA-Approved Treatment for Peanut Allergy</td>
</tr>
<tr>
<td></td>
<td><strong>Investigating the Role of Eosinophils in Health, Airway Disease, and Hypereosinophilic Disorders</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Rediscover Prevention: Proven Efficacy for Patients With HAE</strong></td>
</tr>
<tr>
<td>1:00 – 2:30 pm CST</td>
<td><strong>COVID-19 and Its Impact on Our World, Our Patients and Ourselves</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Hot Topics in Immunotherapy</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Don’t Be Rash! Assessing Contact Dermatitis</strong></td>
</tr>
<tr>
<td></td>
<td><strong>The Spectrum of Dysfunctional Airways</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Practice Management in a Changing Landscape - Efficiency and Legal Issues</strong></td>
</tr>
<tr>
<td>2:35 – 3:00 pm CST</td>
<td><strong>Non-CME Industry Programs:</strong> Understanding Nasal Polyposis</td>
</tr>
<tr>
<td></td>
<td><strong>Type 2 Inflammation</strong></td>
</tr>
<tr>
<td>3:00 – 4:30 pm CST</td>
<td><strong>Addressing Racial and Ethnic Disparities in Allergy/Immunology Populations</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Vaccines: The Good, the Bad and the Scary</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chronic Rhinosinusitis: Prevention, Treatment and Surgery</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Identification and Management of Infant Anaphylaxis</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Allied Health Professionals Program - Inside Out: How To Perform an Environmental Assessment of Our Allergic Patients</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Practice Management in a Changing Landscape - Telemedicine and Cybersecurity</strong></td>
</tr>
<tr>
<td>4:30 – 5:15 pm CST</td>
<td><strong>Town Hall Meeting presented by ACAAI House of Delegates</strong></td>
</tr>
</tbody>
</table>
Schedule at a Glance
All sessions are listed in Central Standard Time (CST).

Friday, November 13 (Continued)

<table>
<thead>
<tr>
<th>4:30 – 5:30 pm CST</th>
<th>5:30 – 6:30 pm CST</th>
</tr>
</thead>
<tbody>
<tr>
<td>L Distinguished Industry Oral Abstracts - Session A</td>
<td>Non-CME Industry Programs:</td>
</tr>
<tr>
<td>L Distinguished Industry Oral Abstracts - Session B</td>
<td>Not for Credit</td>
</tr>
<tr>
<td></td>
<td>L TSLP: A Key Epithelial Cytokine at the Top of the Asthma Inflammatory Cascade</td>
</tr>
<tr>
<td></td>
<td>L A Focus on Type 2 Inflammation in Asthma</td>
</tr>
<tr>
<td></td>
<td>L See EoE: A Closer Look at Diagnosing and Managing Eosinophilic Esophagitis</td>
</tr>
</tbody>
</table>

Saturday, November 14

<table>
<thead>
<tr>
<th>7:00 – 7:55 am CST</th>
<th>9:35 – 10:00 am CST</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-CME Industry Program:</td>
<td>Non-CME Industry Programs:</td>
</tr>
<tr>
<td>Not for Credit</td>
<td>Not for Credit</td>
</tr>
<tr>
<td>L Systemic Mastocytosis: An Allergist/Immunologist Perspective on Diagnosis and Treatment</td>
<td>L Managing Food Allergy During the COVID-19 Pandemic and Implications for the Future</td>
</tr>
<tr>
<td></td>
<td>L Understanding the Needs of Infants and Toddlers With Life-Threatening Allergies</td>
</tr>
<tr>
<td>8:00 – 8:45 am CST</td>
<td>10:00 – 11:00 am CST</td>
</tr>
<tr>
<td>R Advanced Practice Program - Asthma/COPD Overlap</td>
<td></td>
</tr>
<tr>
<td>8:00 – 9:30 am CST</td>
<td>10:00 – 11:30 am CST</td>
</tr>
<tr>
<td>L It’s Time To Individualize Our Approach to Diagnosis and Testing</td>
<td>R Advanced Practice Program - Clinical Pearls From the Dermatologist</td>
</tr>
<tr>
<td>L An International Perspective on Cutting-edge Food Allergy Research</td>
<td></td>
</tr>
<tr>
<td>R The Not on Thursday Program: Cough - Part 1</td>
<td></td>
</tr>
<tr>
<td>R Who Needs Mast Cells Anyway: Non-IgE-mediated Food Allergy</td>
<td></td>
</tr>
<tr>
<td>R Emerging Concepts of IL-5 and Eosinophils in Respiratory Disease</td>
<td></td>
</tr>
<tr>
<td>R Oral Abstracts - Adverse Drug Reactions/Clinical Immunology</td>
<td></td>
</tr>
<tr>
<td>L Nuts and Bolts of Telemedicine</td>
<td></td>
</tr>
<tr>
<td>L School Health for the Allergist</td>
<td></td>
</tr>
<tr>
<td>R The Not on Thursday Program: Biologics - Part 1</td>
<td></td>
</tr>
<tr>
<td>R Joint ACAAI/WAO Presentation - World Allergy Forum: Corticosteroid Stewardship in Allergic Diseases</td>
<td></td>
</tr>
<tr>
<td>R Oral Abstracts - Angioedema/Urticaria</td>
<td></td>
</tr>
<tr>
<td>R Joint ACAAI/AAAAI Session - Ensuring the Success of Academic Allergy</td>
<td></td>
</tr>
</tbody>
</table>
Saturday, November 14 (Continued)

11:35 am – 12:30 pm CST

**Non-CME Industry Programs:**

- Targeting a Common Contributor to Severe Asthma
- A Treatment Option for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months and Older
- The Role of Digitally Connected Inhalers: An Introduction to Digihaler® Technology

3:00 – 4:30 pm CST

- FIT Integrated Educational Program and Business Meeting
- The Not on Thursday Program: Biologics - Part 2
- Beyond Antihistamines: Strategies for Relieving Antihistamine-refractory Chronic Urticaria
- “I’m Sorry Smokey, You Are Over the Line!” The Case for Better Understanding of Allergenic Thresholds and How This Can Improve Patient Care
- CAP (Continuous Assessment Program) Review - Session 2
- Oral Abstracts - Allergy Diagnostics/Aerobiology/Food Allergy
- Editor’s Pick - Best Articles from Annals of Allergy, Asthma & Immunology
- Advanced Practice Program - Psychosocial Management of Food Allergy and Atopic Dermatitis

1:00 – 2:30 pm CST

- Game Show - What’s That Rash? Doctor, What’s Wrong With My Skin?
- The Not on Thursday Program: Cough - Part 2
- How to Discuss Complementary and Alternative Medicine With Patients and Implement Into Practice
- Oral Abstracts - Asthma/Rhinitis
- CAP (Continuous Assessment Program) Review - Session 1
- Advanced Practice Program - Food for Thought on Anaphylaxis

2:35 – 3:00 pm CST

**Non-CME Industry Program:**

- Current Understanding of Hypereosinophilic Syndrome (HES): A Rare Inflammatory Eosinophilic Disease

4:30 – 5:15 pm CST

- ACAAI 2020 Annual Business Meeting

5:15 – 6:15 pm CST

- 29th Annual FIT Bowl

6:15 – 7:15 pm CST

**Non-CME Industry Programs:**

- Disrupting Decades of Unmet Need: Targeting Uncontrolled Asthma & SABA Reliance With PRECISION
- The Journey Towards Controlled Asthma: Shifting the Treatment Paradigm
- Keeping the Cat: A Transformational Approach to Reducing Fel d 1 Through the Cat’s Diet
### Sunday, November 15

#### 8:00 – 8:45 am CST
- **R** Allied Health Professionals Program - The Role of the Nurse in the Care and Management of Patients With Atopic Dermatitis

#### 8:00 – 9:00 am CST
- **R** Oral Abstracts - Clemens von Pirquet Awardees
- **R** Building ABAI Continuing Certification Together

#### 8:00 – 9:30 am CST
- **L** How To Implement Updates From the Latest Clinical Guidelines Into Practice
- **L** SLIT Versus SCIT - Let the Battle Begin
- **R** Literature Review - Morning Program Part 1
- **R** Itching to Help: Diagnosis and Management of Itch and Dermatitis in Special Populations

#### 10:00 – 11:30 am CST
- **L** Coding and Government Relations
- **L** Caring for Patients Across Multiple Populations
- **R** Literature Review - Morning Program Part 2
- **R** Marijuana, E-cigs, Vaping, Hookah and More: How To Discuss With Patients
- **R** EAACI - Allergen Immunotherapy in 2020: Still a Valid Intervention?
- **R** Oral Abstracts - COVID19/Quality Improvement
- **R** Allied Health Professionals Program - Let’s Work Together: Collaborative Patient Care Models in Community Allergy Practices

#### 11:35 am – 12:30 pm CST

**Non-CME Industry Programs:**
- **L** Eosinophilic Immune Dysfunction
- **L** Clinical and Real-World Evidence for Using a Biologic to Treat Severe Eosinophilic Asthma
- **L** Deepening Our Understanding: Cytokine Signaling and the JAK/STAT Pathway in Atopic Dermatitis

#### 1:00 – 2:30 pm CST
- **L** Masqueraders of Common Allergic Conditions
- **L** The AAAAI/ACAAI/CSACI North American Food Allergy Prevention Guidelines
- **R** Literature Review - Afternoon Program Part 1
- **R** The Influence of Social Media on Patients and Medical Decision Making
- **R** Oral Abstracts - Food Allergy
- **R** Allied Health Professionals Program - Oral Challenge Update

#### 3:00 – 4:30 pm CST
- **L** GINA Versus NHLBI Asthma Guidelines: How Do We Reconcile Differences?
- **L** The Challenges of Severe Conjunctival Inflammation
- **R** Literature Review - Afternoon Program Part 2
- **R** Microbiome Across the Spectrum of Allergic Conditions
- **R** Hereditary Angioedema: Rising to the Challenge
- **R** Allied Health Professionals Program - Food Allergy Mimickers: Non-IgE Food Intolerances

---

All sessions are listed in Central Standard Time (CST).
Named Lectures

Each year, the American College of Allergy, Asthma & Immunology presents special named lectures during the Annual Scientific Meeting.

The allergists selected to present named lectures embody the high standards and achievements of the physicians for whom the lectures are named. The College is proud to present the following named lectures at its 2020 Annual Scientific Meeting.

Edward J. O’Connell Memorial Lecture

Lessons Learned From the Skin: How Allergists Can Help Our Patients With Their Common Concerns

Saturday, Nov. 14, 8:45 – 9:05 am CST
Luz S. Fonacier, MD, FACAAI

This annual lectureship was established to honor the legacy of Dr. Edward J. O’Connell, a past president of the College and former *Annals* editor-in-chief, who was a caring, compassionate physician with a life-long passion for serving children. He was an adept educator and authored nearly 100 original articles, along with many book chapters related to allergy and immunology.

Bela Schick Lecture

Then, Now and Where Do We Go From Here?

Saturday, Nov. 14, 9:05 – 9:30 am CST
James M. Tracy, DO, FACAAI

The annual Bela Schick Lecture is named in honor of one of medicine’s most respected scientists. Dr. Bela Schick was born in Hungary and attended medical school in Austria. After serving as Extraordinary Professor of Children's Diseases at the University of Vienna, he immigrated to the United States in 1923. He was a pediatrician at Mt. Sinai in New York for many years, loved by his patients and respected by his fellows. Dr. Schick is best known for his work with Clemens von Pirquet on anaphylaxis and for the test he developed to assess immunity in diphtheria.

Watch and listen live!

8:00 – 9:30 am, CST
Saturday, Nov. 14
Friday, November 13

**7:30 – 8:00 am CST**
Opening Ceremony and Welcome Announcements

J. Allen Meadows, MD, FACAAI, President

David R. Stukus, MD, FACAAI, Annual Meeting Program Chair

**8:00 – 9:30 am CST**
Presidential Plenary

The Changing Payment System – Challenge Accepted!

*Moderator: J. Allen Meadows, MD, FACAAI*

You can play a significant role in ensuring that payment models for hospitals and private practice are fair and comprehensive. Get insight into the future of reimbursement following the presidential election and months spent adjusting for the current and future impact of COVID-19.

**Track:** Practice Management / Professional Issues

8:00 am  Welcome and Introductions
J. Allen Meadows, MD, FACAAI

8:03 am  If You’re Not at the Table, You’re Probably on the Menu!
Bill Finerfrock, President, Capitol Associates; Consultant, Advocacy Council of ACAAI

8:30 am  Keynote Presentation
Why “Value-based Payment” Isn’t Working – And How Physicians Can Fix It
Harold D. Miller, President and CEO Center for Healthcare Quality and Payment Reform

9:20 am  Questions and Discussion

9:30 am  Adjourn

**9:35 – 10:00 am CST**

Industry Program
(See page 64 for details.)

**10:00 – 11:30 am CST**
Guiding Patients Through Peanut Immunotherapy Options

*Moderators: David R. Stukus, MD, FACAAI, and David M. Fleischer, MD, FACAAI*

We now have multiple options available for patients with peanut allergy. This session will discuss how to use shared decision-making to help patients understand treatment options and help allergists understand what their patients value.

**Track:** Food & Drug Allergy and GI Disorders

10:00 am  Welcome and Introductions
David R. Stukus, MD, FACAAI, and David M. Fleischer, MD, FACAAI

10:03 am  Non-FDA-Approved Oral Immunotherapy
Arnon Elizur, MD

10:20 am  FDA-Approved Oral Immunotherapy
Edwin H. Kim, MD, FACAAI

10:35 am  Epicutaneous Immunotherapy
Julie Wang, MD, FACAAI

10:50 am  Ongoing Avoidance Without Treatment
Jay A. Lieberman, MD, FACAAI

11:05 am  Using Shared Decision-making to Guide Patients Through the Options
Matthew C. Greenhawt, MD, MSc, MBA, FACAAI

11:20 am  Questions and Discussion

11:30 am  Adjourn

Looking for the Annual Literature Review? It’s on Sunday this year!
**Approach to Diagnosis and Management of Nasal Polyps in the Biologic Era**

*Moders: John B. Hagan, MD, FACAAI, and Puneet Shroff, MD, FACAAI*

*Supported by an independent educational grant from Genentech*

This session will review nasal polyps and discuss the medical and surgical management of specific endotypes, with a focus on biologic therapies.

**Track:** Clinical Immunology and Autoimmune and Biologicals

10:00 am **Welcome and Introductions**
John B. Hagan, MD, FACAAI, and Puneet Shroff, MD, FACAAI

10:03 am **Description of Underlying Endotypes and Visible Phenotypes Associated With Nasal Polyps**
Sandra Y. Lin, MD

10:30 am **Current Approach to Medical and Surgical Management of Nasal Polyps**
Joshua Levy, MD

10:55 am **The Use of Biologics in Nasal Polyps Based on Disease Mechanism of Individual Phenotypes**
Merin E. Kuruvilla, MD

11:20 am **Questions and Discussion**

11:30 am **Adjourn**

---

**Everything You Wanted To Know About IgG Replacement, but Didn’t Know You Needed To Ask**

*Moders: Purvi S. Parikh, MD, FACAAI, and Lisa J. Kobrynski, MD, MPH, FACAAI*

*Supported in part by an independent educational grant from CSL Behring*

Immunoglobulin replacement can be effective at preventing infection and treating certain inflammatory disorders. However, treatment is often complicated by adverse reactions. Multiple gamma globulin products are currently available, and choosing the best product for the individual patient can decrease the burden of treatment and improve adherence to this therapy.

**Track:** Clinical Immunology and Autoimmune and Biologicals

10:00 am **Welcome and Introductions**
Purvi S. Parikh, MD, FACAAI, and Lisa J. Kobrynski, MD, MPH, FACAAI

10:03 am **Immunoglobulin Replacement: The Proper Indications for Starting Therapy and Continuing Therapy**
Vivian P. Hernandez-Trujillo, MD, FACAAI

10:40 am **Immunoglobulin Replacement: Pearls for Managing Antibody Deficient Patients on Immunoglobulin Replacement Therapy**
Mark M. Ballow, MD, FACAAI

11:20 am **Questions and Discussion (Online Chat)**

11:30 am **Adjourn**

---

**Time Zones**

All sessions are listed in Central Standard Time (CST). Don’t forget to convert them to your local time zone when planning your schedule!
Friday, November 13

**Joint ACAAI/AAP-SOA Session**

**7 for 11: Hot Topics in Pediatric A/I**

*Moderator: Todd A. Mahr, MD, FACAAI*

Each of the 7 presenters will have only 11 minutes to deliver insightful, targeted and dynamic information on their assigned topics.

**Track: Dermatology**

- **Welcome and Introductions**
  Todd A. Mahr, MD, FACAAI

- **Asthma**
  Angela D. Hogan, MD, FACAAI

- **Food Allergy - Non-treatment**
  J. Wesley Sublett, MD, MPH, FACAAI

- **Food Allergy - Treatment**
  J. Andrew Bird, MD, FACAAI

- **Biologics**
  Carla M. Davis, MD, FACAAI

- **Anaphylaxis**
  Julie Wang, MD, FACAAI

- **Immunology**
  Mary Beth Fasano, MD, MSPH, FACAAI

- **Epidemiology**
  Ruchi Gupta, MD, MPH

- **Adjourn**

**Practice Management in a Changing Landscape – Billing and Coding Update**

*Moderator: Thomas J. Derrico*

**Track: Practice Management / Professional Issues**

10:00 am  **Welcome and Introductions**
Thomas J. Derrico

10:10 am  **Coding/Billing/Regulatory Update**
Gary N. Gross, MD, FACAAI

11:00 am  **ACAAI College Resources To Help Your Practice**
Jennifer Pfeifer, MBA, CMPE

11:10 am  **Questions and Discussion (Online Chat)**

11:30 am  **Adjourn**

---

**NOT FOR CREDIT**

11:35 am – 12:30 pm CST

**Industry Programs**

*(See page 64 for details.)*
L LIVE RECORDED+ RECORDED

Friday, November 13

1:00 – 2:30 pm CST
COVID-19 and Its Impact on Our World, Our Patients and Ourselves
Moderator: Brian T. Kelly, MD, MA, FACAAI
The crushing coronavirus emergency has attacked our physicians on all fronts: caring for compromised patients, dispelling harmful misinformation, significantly changing business models, keeping our families safe and maintaining the agility to forge ahead. This session will provide strategies to help our patients and ourselves successfully survive this pandemic.

1:00 pm Welcome and Introductions
Brian T. Kelly, MD, MA, FACAAI

1:03 pm How Best to Battle the Infodemic
Timothy Caulfield, LLM, FRSC, FCAHS

1:25 pm Immunology, Risk Factors, and Treatment of COVID-19
Brian Lipworth, MD, FACAAI

1:50 pm Learning To Live With COVID-19: Strategies To Help Medical Professionals and Our Patients
Jessi Gold, MD, MS

2:15 pm Questions and Discussion

2:30 pm Adjourn

1:00 – 2:30 pm CST
Hot Topics in Immunotherapy
Moderators: Ellen R. Sher MD, FACAAI, and Peter J. Mustillo, MD, FACAAI
While we currently have 19 standardized subcutaneous allergens in the United States, there are several different methods used to describe standardized allergens. In Europe there are standardization terms that are unfamiliar to many U.S. allergists. It is important for the practicing allergist to understand the methodologies for the standardization of allergen extracts and how the standardized allergens may influence clinical allergen immunotherapy in the U.S.

Track: Immunotherapy and Diagnostics

1:00 pm Welcome and Introductions
Ellen R. Sher MD, FACAAI, and Peter J. Mustillo, MD, FACAAI

1:03 pm Are You Dosing Properly?
Harold S. Nelson, MD, FACAAI

1:30 pm Do Patients Receiving Subcutaneous Immunotherapy Need To Have an Epinephrine Auto-injector Prescribed?
David I. Bernstein, MD, FACAAI

Jay M. Portnoy, MD, FACAAI

2:20 pm Questions and Discussion

2:30 pm Adjourn

Scheduled Break Times
Grab your favorite snack and visit the interactive virtual exhibit hall, e-posters and the networking lounge.
Friday, November 13

**Never Miss a Beat: A Day of Updates, Education, and Networking**

**Don’t Be Rash! Assessing Contact Dermatitis**

Moderators: Sandra M. Gawchik, DO, FACAAI, and Tammy Peng, MD

From basic science to the clinical conundrums, this session will cover how to evaluate and manage patients with contact dermatitis.

Track: Dermatology

1:00 pm Welcome and Introductions
Sandra M. Gawchik, DO, FACAAI, and Tammy Peng, MD

1:03 pm Interpretation of Skin Biopsy Results in Eczema
Whitney A. High, MD, MEng

1:28 pm Clinical Pearls and Pitfalls in Evaluating Patients With Contact Dermatitis
Sharon E. Jacob, MD

1:53 pm How To Help Patients With Contact Dermatitis Before and After Patch Testing
Jeff J. Yu, MD

2:20 pm Questions and Discussion (Online Chat)

2:30 pm Adjourn

**The Spectrum of Dysfunctional Airways**

Moderators: Jeremy S. Katcher, MD, FACAAI, and Michael R. Rupp, MD, FACAAI

This session will review dysfunctional breathing in children and adults. Various aspects of the upper airway will be discussed, including how allergists can help identify and treat patients who have obstructive sleep apnea and exercise-induced laryngeal obstruction.

Track: Asthma and Respiratory / Sleep Disorders

1:00 pm Welcome and Introductions
Jeremy S. Katcher, MD, FACAAI, and Michael R. Rupp, MD, FACAAI

1:03 pm Obstructive Sleep Apnea: More Than Snoring – Allergists Can Help
Timothy J. Craig, DO, FACAAI

1:35 pm Diagnosing Exercise-induced Laryngeal Obstruction and Dysfunctional Breathing
James Tod Olin, MD, MSCS

1:53 pm Advances in Treatment and Behavioral Interventions To Treat EILO
Monica Shaffer, MA, CCC-SLP

2:20 pm Questions and Discussion (Online Chat)

2:30 pm Adjourn

**Practice Management in a Changing Landscape – Efficiency and Legal Issues**

Moderator: Thomas J. Derrico

Track: Practice Management / Professional Issues

1:00 pm Welcome and Introductions
Thomas J. Derrico

1:03 pm Practice Efficiency: Work Flow/Lean Six Sigma
Michael Tankersley, MD, MBA, FACAAI

1:35 pm Legal Issues in Practice
Denise Yarborough, JD, Esq.

2:20 pm Questions and Discussion (Online Chat)

2:30 pm Adjourn
3:00 – 4:30 pm CST

Addressing Racial and Ethnic Disparities in Allergy/Immunology Populations

Moderator: David R. Stukus, MD, FACAAI

This session will discuss how allergists can understand racial and ethnic disparities and address these issues with respect to caring for patients with food allergy, asthma and atopic dermatitis.

Track: Population Health and Infectious Diseases / International Travel

3:00 pm Welcome and Introductions
   David R. Stukus, MD, FACAAI

3:03 pm Atopic Dermatitis Disparities
   Jonathan Silverberg, MD, PhD, MPH

3:30 pm Asthma Disparities
   Tamara T. Perry, MD

3:55 pm Food Allergy Disparities
   Carla Davis, MD, FACAAI

4:20 pm Questions and Discussion

4:30 pm Adjourn

---

Vaccines: The Good, the Bad and the Scary

Moderators: Melinda M. Rathkopf, MD, FACAAI, and Mervat Nassef, MD, FACAAI

Recent events, including an unprecedented global pandemic and the 2019 measles outbreak, highlight the importance of universal vaccination. However, parents of young children do not always comply with recommended vaccinations for various reasons, including fear of vaccine-related adverse reaction. Allergists/immunologists can play an important role in improving vaccination rates by dispelling unfounded fears, evaluating patients with suspected adverse reactions and assessing risk in patients with severe allergy to vaccine ingredients.

Track: Population Health and Infectious Diseases / International Travel

3:00 pm Welcome and Introductions
   Melinda M. Rathkopf, MD, FACAAI, and Mervat Nassef, MD, FACAAI

3:03 pm Lessons Learned From Recent Outbreaks and How To Deal With Vaccine Hesitancy
   Lisa Saiman, MD, MPH

3:30 pm Evaluation and Management of Adverse Reactions to Vaccines
   John M. Kelso, MD, FACAAI

3:55 pm Vaccine Development: Why? When? How?
   Julie E. Ledgerwood, DO

4:20 pm Questions and Discussion

4:30 pm Adjourn
Friday, November 13

**3:00 – 4:30 pm CST**

**Chronic Rhinosinusitis: Prevention, Treatment and Surgery**

*Moderator: J. Wesley Sublett, MD, MPH, FACAAI*

Chronic rhinosinusitis is a common condition impacting millions of patients. This session will discuss the common causes and contributing factors that allergists should consider during evaluation. In addition, various medical and surgical treatment approaches will be discussed, including how to discuss and choose the best options for each individual patient.

**Track:** Rhinitis / Sinusitis / Ocular and Anaphylaxis

**Welcome and Introductions**
J. Wesley Sublett, MD, MPH, FACAAI

**Causes, Contributing Factors and Evaluation of the Patient**
Jonathan A. Bernstein, MD, FACAAI

**Medical Therapies**
Whitney Stevens, MD, PhD

**Today’s Surgical Options and Outcomes**
Thomas S. Higgins, MD, MSPH

**Adjourn**

---

**3:00 – 4:30 pm CST**

**Identification and Management of Infant Anaphylaxis**

*Moderators: Michael Pistiner, MD, MMSc, FACAAI, and Kristin C. Sokol, MD, MS, MPH, FACAAI*

Infants present with different signs and symptoms of anaphylaxis, as compared to older patients. Attendees will be able to identify anaphylaxis in infants and educate the parents/family members of these infants. Proper management and treatment will also be reviewed.

**Track:** Rhinitis / Sinusitis / Ocular and Anaphylaxis

3:00 pm **Welcome and Introductions**
Michael Pistiner, MD, MMSc, FACAAI, and Kristin C. Sokol, MD, MS, MPH, FACAAI

3:03 pm **Epidemiology and Presentation of Infant Anaphylaxis – Signs and Symptoms**
Vivian P. Hernandez-Trujillo, MD, FACAAI

3:30 pm **Treatment and Management of Infant Anaphylaxis**
Jay A. Lieberman, MD, FACAAI

3:55 pm **Infants in the Office Setting: Practical Aspects of Early Peanut Introduction and Oral Food Challenges**
Justin Greiwe, MD, FACAAI

4:20 pm **Questions and Discussion (Online Chat)**

4:30 pm **Adjourn**

---

Thinking about becoming a member? [Learn about the benefits here.](#)
Friday, November 13

**Practice Management in a Changing Landscape – Telemedicine and Cybersecurity**

*Moderator: Thomas J. Derrico*

**Track:** Practice Management / Professional Issues

**Welcome and Introductions**
Thomas J. Derrico

**Telehealth in Private Practice: Optimizing and Enhancing for the Future**
Tania Elliott, MD, FACAAI

**Cyber Security: Recognizing, Assessing and Mitigating Risks**
Joseph Alessi

**Adjourn**

---

**Allied Health Professionals Program**

**Inside Out: How To Perform an Environmental Assessment of Our Allergic Patients**

*Supported by an independent educational grant from Aimmune Therapeutics*

This session will discuss everything you wanted to know about pollen and molds. It will begin by reviewing pollen identification with seasonal and regional variations. Next, we'll go indoors and review how to perform a home assessment for allergens in the home. This session is designed for all healthcare workers in the field of allergy.

*Educational credit for the Allied Health Professionals Course is only available to those who pre-registered for it.*

**Welcome and Introductions**
Jodi A. Shroba, MSN, APRN, CPNP

**Let’s Take It Outside: A Review of Pollens and Molds**
Amanda L. Michaud, PA-C

**Bringing It Home: How To Perform a Home Assessment**
Kevin Kennedy, MPH, CIEC

**Adjourn**

---

**Town Hall Meeting presented by ACAAI House of Delegates**

All attendees are invited to participate. Learn about new resolutions and what telehealth will look like post COVID-19.

**Speakers:**

Curtis L. Hedberg, MD, FACAAI, Speaker of the ACAAI House of Delegates
Bill Finerfrock, President of Capitol Associates, Consultant to Advocacy Council of ACAAI

I. Welcome and Officer Introductions
II. Business Meeting
   a. Approve Minutes
   b. Recording Secretary and Super-delegate Voting
   c. Resolutions
III. Introduction of State Delegates
IV. Summary of Regional Town Hall Meetings
V. What Will Telehealth Look Like Post COVID-19?
Friday, November 13

**4:30 – 5:30 pm CST**

**Distinguished Industry Oral Abstracts – Session A**

*Moderator: Todd A. Mahr, MD, FACAAI*

The College is honored to provide an opportunity for industry to update our attendees on the latest research and developing opportunities for patient treatment.

- **4:30 pm** Welcome and Introductions
  Todd A, Mahr, MD, FACAAI

- **4:33 pm** Abrocitinib Versus Dupilumab: Time to Improvement by Body Region (JADE COMPARE)
  Marjolein De Brun-Weller, MD

- **4:43 pm** Ligelizumab Achieves Fast Control of Symptoms in More Patients With Chronic Spontaneous Urticaria Versus Omalizumab
  Thomas Severin, MD

- **4:53 pm** Efficacy of Ligelizumab in Patients With Chronic Spontaneous Urticaria Inadequately Controlled With Omalizumab
  Gordon Sussman, MD

- **5:03 pm** Berotralstat Reduces Attacks in Patients With Hereditary Angioedema (HAE): APeX-2 Trial 48 Week Results
  H. James Wedner, MD

- **5:13 pm** Questions and Discussion

- **5:30 pm** Adjourn

**4:30 – 5:30 pm CST**

**Distinguished Industry Oral Abstracts – Session B**

*Moderator: Melanie A. Ruffner, MD, PhD*

The College is honored to provide an opportunity for industry to update our attendees on the latest research and developing opportunities for patient treatment.

- **4:30 pm** Welcome and Introductions
  Melanie A. Ruffner, MD, PhD

- **4:33 pm** Development of an EHR-Based Algorithm To Identify Patients With Chronic Cough
  Vishal Bali, MD

- **4:43 pm** Patients With Chronic Rhinosinusitis With and Without Asthma: A Real-world Experience
  Hector Ortega, MD

- **4:53 pm** Continued Safety/Efficacy of Omalizumab in Chronic Rhinosinusitis With Nasal Polyps: An Open-label Extension Study
  Philippe Gevaert, MD

- **5:03 pm** Questions and Discussion

- **5:30 pm** Adjourn

---

*5:30 – 6:30 pm CST*  
Industry Programs  
*(See page 65 for details.)*
8:00 – 9:30 am CST

It’s Time To Individualize Our Approach to Diagnosis and Testing

_**Moderator: Mark L. Corbett, MD, FACAAI**_

This plenary will provide dynamic presentations surrounding important topics that have evolved in recent years. Allergists are in a unique position to provide education to patients and help them understand their risk from various scenarios. The field of component diagnostic testing for food, inhalant and venom allergens has rapidly expanded, and attendees will learn how to utilize and interpret various tests. Attendees will also learn how to apply specialty training in allergy and immunology to address common concerns from patients regarding dermatologic conditions.

**Track: Immunotherapy and Diagnostics**

**8:00 am**
**Welcome and Introductions**
Mark L. Corbett, MD, FACAAI

**8:03 am**
**How To Discuss Complicated Concepts Surrounding Risk With Patients**
Elissa M. Abrams, MD

**8:25 am**
**Component-resolved Diagnostics – Which Ones Are Ready for Prime Time?**
Giorgio Walter Canonica, MD

**8:45 am**
**Edward J. O’Connell Lecture**

*Lessons Learned From the Skin: How Allergists Can Help Our Patients With Their Common Concerns*
Luz S. Fonacier, MD, FACAAI

**9:05 am**
**Bela Schick Lecture**

*Then, Now and Where Do We Go From Here?*
James M. Tracy, DO, FACAAI

**9:30 am**
Adjourn

---

8:00 – 9:30 am CST

An International Perspective on Cutting-edge Food Allergy Research

_**Moderators: Ruchi Gupta, MD, MPH, and Benjamin Prince, MD**_

In this session, attendees will be given an in-depth perspective on the outcomes and knowledge gained from the Australian HealthNuts prospective, population-based food allergy prevalence study at 10 years in terms of the development, risk factors for development and natural history of food allergy. In addition, this session will detail the next frontier in food allergy prevention from studies ongoing in the Center for Food Allergy Research consortium across Australia, detailing their work into early tree nut introduction and how vitamin D, maternal diet and vaccines may influence the development of food allergy in the infant. Lastly, the attendee will learn about cutting-edge ongoing research from Israel regarding tree nut oral immunotherapy and how desensitization to one tree nut can protect against multiple tree nut allergies.

**Track: Food & Drug Allergy and GI Disorders**

**8:00 am**
**Welcome and Introductions**
Ruchi Gupta, MD, MPH, and Benjamin Prince, MD

**8:05 am**
**The HealthNuts Study at Age 10: Lessons Learned and Future Directions**
Jennifer Koplin, MD, PhD

**8:55 am**
**Questions and Discussion**

**9:30 am**
Adjourn
Saturday, November 14

**8:00 – 9:30 am CST**

**The Not on Thursday Program: Cough – Part 1**

*Moderators: Alan B. Goldsobel, MD, FACAAI, and David R. Stukus, MD, FACAAI*

*Supported by an independent educational grant from Merck*

From diagnosis to treatment, this session will highlight the evolution of cough, current treatment guidance options, and a look into future therapies.

**Track: Asthma and Respiratory / Sleep Disorders**

- **Welcome and Introductions**
  - Alan B. Goldsobel, MD, FACAAI, and David R. Stukus, MD, FACAAI

- **Choosing the Proper Test From Your Diagnostic Tool Belt**
  - Mandel R. Sher, MD, FACAAI

- **Kids Are Not Little Adults: Unique Aspects to Diagnosis and Treatment of Cough in Children**
  - William C. Anderson, MD, FACAAI

- **The Future Is Bright: Hopeful Options for Asthma**
  - Leonard B. Bacharier, MD, FACAAI

**Adjourn**

---

**8:00 – 9:30 am CST**

**Who Needs Mast Cells Anyway: Non-IgE-mediated Food Allergy**

*Moderators: Anna H. Nowak-Wegrzyn, MD, FACAAI, and Irene Mikhail, MD*

Non-IgE-mediated food intolerances and allergies are common concerns among patients. This session will address the current evidence and understanding of how to recognize the features pertaining to common conditions, decide what tests to utilize to assist diagnosis and review treatment options.

**Track: Food & Drug Allergy and GI Disorders**

- **Welcome and Introductions**
  - Anna H. Nowak-Wegrzyn, MD, FACAAI, and Irene Mikhail, MD

- **FPIES – Prevalence, Diagnosis and Management Pearls**
  - Terri F. Brown-Whitehorn, MD

- **Eosinophilic Esophagitis**
  - Antonella Cianferoni, MD

- **Allergic Proctocolitis and Other Crimes Against Humanity Attributed to Milk**
  - J. Andrew Bird, MD, FACAAI

**Adjourn**
Emerging Concepts of IL-5 and Eosinophils in Respiratory Disease

Moderators: Jeremy S. Katcher, MD, FACAII, and Alan B. Goldsobel, MD, FACAII

Over the last few years, we have continued to learn more about how IL-5 and eosinophils often mediate severe asthma and other related conditions. However, our understanding is still incomplete. The ability to determine to what extent this pathway is responsible for asthma pathophysiology can still be challenging. Similarly, with multiple biologics available, it can be difficult for the asthma specialist to determine which specific agent is most appropriate and beneficial to the patient. Determining the most accurate and clinically meaningful biomarkers would be a major step in this process. With better understanding of the pathophysiology, and continuing education of asthma specialists, multiple healthcare benefits could be realized. Patient care and asthma control would improve maximally and most expeditiously with the best choice of biologic being made initially. This would help decrease healthcare dollars spent on exacerbations, ED visits, hospitalizations, as well as minimize patient job/school absenteeism.

Track: Asthma and Respiratory / Sleep Disorders

8:00 am Welcome and Introductions
Jeremy S. Katcher, MD, FACAII, and Alan B. Goldsobel, MD, FACAII

8:03 am Subtypes of Severe Asthma With Emphasis on Eosinophilic Subtype
William C. Anderson, MD, FACAII

8:28 am Biomarker Interpretations and How This Would Aid in Treatment Choice and Prognosis Prediction
Leonard B. Bacharier, MD, FACAII

8:53 am IL-5/Eosinophil-related Conditions Other Than Severe Eosinophilic Asthma
Princess Ogbogu, MD, FACAII

9:20 am Questions and Discussion (Online Chat)

9:30 am Adjourn
Saturday, November 14

**Advanced Practice Program – Asthma/COPD Overlap**

*Moderator: Jodi A. Shroba, MSN, APRN, CPNP*

Previously thought to be two separate disease states, it is now widely accepted that some patients exhibit a mixed asthma and COPD presentation. This session will explore the diagnosis and management of this challenging patient population.

*Educational credit for the Advanced Practice Health Care Providers Course is only available to those who pre-registered for it.*

**Welcome and Introductions**
Jodi A. Shroba, MSN, APRN, CPNP

**Asthma/COPD Overlap**
Michelle R. Dickens, MSN, RN, FNP-C, AE-C

**Adjourn**

---

**Nuts and Bolts of Telemedicine**

*Moderators: Jay M. Portnoy, MD, FACAAI, and David M. Lang, MD, FACAAI*

This session will focus on helping practicing allergists set up a telemedicine program in their office, as well as bill and get paid for providing the service. Attendees will also get tips on how to see patients using this technology.

**Track: Practice Management / Professional Issues**

**Welcome and Introductions**
Jay M. Portnoy, MD, FACAAI, and David M. Lang, MD, FACAAI

**The Changing Paradigm of Telemedicine**
Jennifer A. Shih, MD

**How To Implement Telemedicine Into Your Practice**
Tania Elliott, MD, FACAAI

**Coding and Billing for Telemedicine Services: How To Get Started and How To Get Paid**
Sakina S. Bajowala, MD

**Questions and Discussion**

**Adjourn**

---

**Scheduled Break Times**

Grab your favorite snack and visit the interactive virtual exhibit hall, e-posters and the networking lounge.
Saturday, November 14

**L 10:00 - 11:30 am CST**

**School Health for the Allergist**

*Moderators: Bruce J. Lanser, MD, FACAAI, and Irene Mikhail, MD*

With the rise in prevalence of multiple childhood allergic diseases, schools have been forced to deal with management facets to ensure that students remain safe and healthy at school. As well, schools have represented opportunities to reach populations who may otherwise lack access to healthcare services to both diagnose and manage allergic diseases. This session will detail the approach to the care of managing the patient with allergic disease in the school setting and discuss challenges and opportunities of how to deliver care in school-based settings.

**Track:** Food & Drug Allergy and GI Disorders

10:00 am  **Welcome and Introductions**  
Bruce J. Lanser, MD, FACAAI, and Irene Mikhail, MD

10:03 am  **Improving the Health of Students: Successful Approaches to Community Partnerships With Schools**  
Michael Pistiner, MD, MMSc, FACAAI

10:30 am  **Food Allergies and Anaphylaxis in Schools**  
Julie Wang, MD, FACAAI

10:55 am  **Wheezing in the Classroom: School-based Asthma Management**  
Sujani Kakumanu, MD

11:20 am  **Questions and Discussion**

11:30 am  Adjourn

**R 10:00 - 11:30 am CST**

**The Not on Thursday Program: Biologics – Part 1**

*Moderators: John J. Oppenheimer, MD, FACAAI, and Brian T. Kelly, MD, MA, FACAAI*

Cutting-edge biologics can offer promising results. This session will focus on the latest information on current and emerging applications for sinus disease, skin afflictions and food allergy.

**Track:** Immunotherapy and Diagnostics

**Welcome and Introductions**  
John J. Oppenheimer, MD, FACAAI and Brian T. Kelly, MD, MA, FACAAI

10:00 am  **It’s a Unified Airway: Options for Sinus Disease**  
Anju T. Peters, MD

10:30 am  **Current and Emerging Biologics in Atopic Dermatitis**  
Mark Boguniewicz, MD, FACAAI

10:55 am  **Beyond OIT: How Biologics Can Help Patients With Food Allergy**  
David M. Fleischer, MD, FACAAI

11:20 am  Adjourn
The evidence shows that there are consequences of using oral corticosteroids (OCS) even in low doses. Overuse of OCS presents even more challenges up to, and including, mortality. Thus, there is a high cost involved in OCS overuse due to side effects. Even though biologics are expensive, they do offer an alternative to OCS. OCS overuse is relevant in GI and pulmonology as well as allergy.

Track: Asthma and Respiratory / Sleep Disorders

Welcome and Introductions
ACAAI President J. Allen Meadows, MD, FACAAI, and WAO President Motohiro Ebisawa, MD

Effects of Corticosteroids on Human Health
Eugene R. Bleecker, MD

Health Consequences of Overuse of Corticosteroids
Arnaud Bourdin, MD

Economic Impacts - Cost of Side Effects From Overuse of Corticosteroids
Giorgio Walter Canonica, MD

Adjourn
Saturday, November 14

**R** 10:00 - 11:30 am CST

Joint ACAAI/AAAAI Session

**Ensuring the Success of Academic Allergy**

*Moderators: Bryan L. Martin, DO, FACAAI, and Aidan A. Long, MD*

This program is designed to bring together academic allergy/immunology leaders, including department/division/section leaders, associate leaders and program directors, to hear about work that has been done by the task force and to provide additional input into the task force deliberations. The overall effort is to create a viable and energetic network of academic allergy/immunology leaders who can ensure that the profession survives and thrives in the changing academic environment.

**Track:** Practice Management / Professional Issues

**Welcome and Introductions**
Bryan L. Martin, DO, FACAAI, and Aidan A. Long, MD

**Joint Task Force Update**
Bryan L. Martin, DO, FACAAI

**Increasing the Scope and Visibility of Your Academic Division**
Aidan A. Long, MD

**Overcoming Financial Issues in the Academic Allergy/Immunoology Division**
Kevin J. Kelly, MD, FACAAI

**Adjourn**

---

**R+** 10:00 - 11:00 am CST

Advanced Practice Program

**Clinical Pearls From the Dermatologist**

*Moderator: Jodi A. Shroba, MSN, APRN, CPNP*

While practicing in allergy, health care practitioners are often asked about a rash or other skin conditions. This session will improve their diagnosis and management skills for common skin conditions that may present in the allergy office.

*Educational credit for the Advanced Practice Health Care Providers Course is only available to those who pre-registered for it.*

10:00 am **Welcome and Introductions**
Jodi A. Shroba, MSN, APRN, CPNP

10:03 am **Clinical Pearls From the Dermatologist**
Marc Serota, MD

10:45 am **Questions and Discussion (Online Chat)**

11:00 am **Adjourn**

---

**11:35 am - 12:30 pm CST**

**Industry Programs**

(See page 67 for details.)
Saturday, November 14

**What’s That Rash? Doctor, What’s Wrong With My Skin?**

*Host: Stephanie L. Mawhirt, DO*

This session is designed to assist the attendee in developing a better understanding of terms used to diagnose various skin conditions, recognize common and similar patterns of skin disease and formulate a treatment strategy. Rapid fire, high yield and fun, all rolled into one.

**Track:** Dermatology

**Faculty:** Kelly M. Maples, MD, FACAAI; Luz S. Fonacier, MD, FACAAI, and James Treat, MD

1:00 pm  Welcome and Introductions  
Stephanie L. Mawhirt, DO

1:05 pm  Game Time!

2:20 pm  Questions and Discussion

**How to Discuss Complementary and Alternative Medicine With Patients and Implement Into Practice**

*Moderators: William S. Silvers, MD, FACAAI, and Payel Gupta, MD, FACAAI*

According to recent data from the NIH and Natural Center for Health Statistics, approximately 38% of adults and 12% of children use some form of integrative medicine, while more than 60% of allergy sufferers try a natural product. This has significant impact on the traditional practice of medicine. There is a need to improve our recognition and understanding of integrative medicine (“complementary and alternative”) therapies in the field of allergy and immunology. This session is designed as an introductory course to educate allergy and immunology specialists on the most common integrative medicine therapies being used in our field.

**Track:** Environmental and Integrative Medicine

1:00 pm  Welcome and Introductions  
William S. Silvers, MD, FACAAI, and Payel Gupta, MD, FACAAI

1:03 pm  Bringing It Into Your Practice  
Anil Nanda, MD, FACAAI

1:30 pm  Practical Tips  
Dipa K. Sheth, MD, FACAAI

1:55 pm  What Does the Evidence Support?  
Gary K. Soffer, MD

2:20 pm  Questions and Discussion (Online Chat)

2:30 pm  Adjourn
Saturday, November 14

**Oral Abstracts – Asthma/Rhinitis**

Moderator: J. Wesley Sublett, MD, MPH, FACAAI

1:00 pm  **Welcome and Introductions**
J. Wesley Sublett, MD, MPH, FACAAI

1:03 pm  **Tezepelumab Efficacy in Severe Asthma by Specific Allergen Sensitivity: Results From the PATHWAY Study**
Jonathan Corren, MD, FACAAI

1:18 pm  **Eosinophilia (>300/ul) Marks Small Airway Obstruction Irrespective of Allergic Sensitization in Inner-city Severe Asthmatics**
Granit Mavraj, MD

1:33 pm  **Changes in Nasal Airflow With Loratadine-pseudoephedrine Versus Fluticasone Spray After First Dose for Allergy**
Anne K. Ellis, MD, MSc, FACAAI

1:48 pm  **Serum IL-6 Levels in Patients With Aspirin-exacerbated Respiratory Disease**
Anuj Kapil, MD

2:03 pm  **House Dust Mite Environmental Exposure Unit: Clinical Validation of a Model for Perennial Allergic Rhinitis**
Lubnaa Hossenbaccus

2:18 pm  **Questions and Discussion (Online Chat)**

2:30 pm  **Adjourn**

---

**Continuous Assessment Program (CAP) Review – Session 1**

Moderator: Brian T. Kelly, MD, MA, FACAAI

The CAP Review is a literature-style review covering most of the articles chosen by the ABAI for the current six-month cycle of the Continuous Assessment Program (CAP). Each presenter will focus on key aspects of the study design, results and implications for practice. The goal of this session is to help prepare attendees for the first cycle of ABAI CAP program.

*Due to the impacts of COVID-19 on physicians, ABAI has canceled Block 2 for 2020. The completion of the Block 1 Continuous Assessment Program has been extended to January 15, 2021.*

**Track: Asthma and Respiratory / Sleep Disorders**

1:00 pm  **Welcome and Introductions**
Brian T. Kelly, MD, MA, FACAAI

1:03 pm  **Head/Neck**
Jeremy Katcher, MD, FACAAI

1:06 pm  **Dermatologic**
Kelly M. Maples, MD, FACAAI

1:09 pm  **Lung/Food & Drug Allergy/ Hypersensitivity Reactions**
Brian T. Kelly, MD, MA, FACAAI

2:30 pm  **Adjourn**
1:00 – 2:30 pm CST
Advanced Practice Program
Food for Thought on Anaphylaxis

Moderator: Jodi A. Shroba, MSN, APRN, CPNP

Idiopathic anaphylaxis can be frustrating and challenging for both patients and clinicians. This session will explore the diagnosis and management of this condition along with the latest recommendations for management of anaphylaxis from any cause.

Alpha-gal allergy is a delayed allergic reaction to the ingestion of mammalian meats which contains the sugar or carbohydrate alpha gal (glactose-alpha-1, 3-galactose). This allergy is triggered by a tick bite. This session will review the development and management of this tick-borne allergy.

Educational credit for the Advanced Practice Health Care Providers Course is only available to those who pre-registered for it.

Welcome and Introductions
Jodi A. Shroba, MSN, APRN, CPNP

Idiopathic Anaphylaxis and Updates on Anaphylaxis Management
Julie Wang, MD, FAAAAI

Just One Bite Can Cause a Food Allergy: A Review of Alpha-gal
Scott Commins, MD, PhD

Adjourn

3:00 – 4:30 pm CST
FIT Integrated Educational Program & Business Meeting

3:00 pm  Welcome and Introductions
Miriam Samstein, MD, and
Timothy Chow, MD

3:10 pm  Junior FIT Representative Candidate Speeches & Voting

3:25 pm  Career Panel
Angela Hogan, MD, FAAAAI; Anil Nanda, MD, FAAAAI; and
Stephen Tilles, MD, FAAAAI

4:25 pm  Announcement of 2020-2021 Junior FIT Representative and Closing Remarks

4:30 pm  Adjourn

3:00 – 4:30 pm CST
The Not on Thursday Program: Biologics

Moderators: John J. Oppenheimer, MD, FAAAAI, and
Brian T. Kelly, MD, MA, FAAAAI

Track: Immunotherapy and Diagnostics

3:00 pm  Welcome and Introductions
John J. Oppenheimer, MD, FAAAAI, and
Brian T. Kelly, MD, MA, FAAAAI

3:03 pm  Navigating Current Asthma Choices
Thomas B. Casale, MD, FAAAAI

3:45 pm  Cost-effectiveness of Biologics
Stanley J. Szefler, MD, FAAAAI

4:20 pm  Questions and Discussion

4:30 pm  Adjourn
Beyond Antihistamines: Strategies for Relieving Antihistamine-refractory Chronic Urticaria

Moderators: Kelly M. Maples, MD, FACAAI, and Joseph P. Forester, DO, FACAAI

The management of chronic urticaria has evolved in recent years, but several mainstays can continue to offer benefit. This session will review the evidence surrounding older approaches, current approaches and what potential treatment options may be available. The important aspect of helping patients beyond medication and addressing the significant psychosocial impact of refractory chronic urticaria will also be addressed.

Track: Dermatology

3:00 pm  Welcome and Introductions
Kelly M. Maples, MD, FACAAI, and Joseph P. Forester, DO, FACAAI

3:03 pm  Omalizumab for Antihistamine-refractory Urticaria
Sarbjit S. Saini, MD

3:25 pm  Emerging Therapies for Refractory Urticaria
David A. Khan, MD, FACAAI

3:50 pm  Evidence for Other Biologics in Refractory Urticaria
Marc Serota, MD

4:15 pm  Questions and Discussion (Online Chat)

4:30 pm  Adjourn

“I’m Sorry Smokey, You Are Over the Line!” The Case for Better Understanding of Allergenic Thresholds and How This Can Improve Patient Care

Moderators: Douglas P. Mack, MD, MSc, and Brian T. Kelly, MD, MA, FACAAI

The concept of allergenic thresholds remains elusive and controversial. While there is evidence that these exist, there is also uncertainty in how these can be established and regulated and how they may vary at a patient level. Understanding of thresholds has broad social and medico-legal impact with respect to how patients are being managed and how products are labeled at stores and in restaurants.

Track: Food & Drug Allergy and GI Disorders

Welcome and Introductions
Douglas P. Mack, MD, MSc, and Brian T. Kelly, MD, MA, FACAAI

Understanding Variability in Threshold Response
Andrew Clark, MD

Understanding the Regulatory Climate for Threshold Labeling
Stefano Luccioli, MD

The Australian Experience Regarding VITAL
Jennifer Koplin, MD, PhD

Adjourn
Saturday, November 14

3:00 – 4:30 pm CST

Continuous Assessment Program (CAP) Review – Session 2

Moderator: Brian T. Kelly, MD, MA, FACAAI

The CAP Review is a literature-style review covering most of the articles chosen by the ABAI for the current six-month cycle of the Continuous Assessment Program (CAP). Each presenter will focus on key aspects of the study design, results and implications for practice. The goal of this session is to help prepare attendees for the first cycle of ABAI CAP program.

Due to the impacts of COVID-19 on physicians, ABAI has canceled Block 2 for 2020. The completion of the Block 1 Continuous Assessment Program has been extended to January 15, 2021.

Track: Practice Management / Professional Issues

Welcome and Introductions
Brian T. Kelly, MD, MA, FACAAI

Anaphylaxis
Anne K. Ellis, MD, MSc, FACAAI

Immune Hypersensitivity Disorders
Nikita Raje, MD, FACAAI

Immunodeficiencies
Benjamin Prince, MD

Eosinophilic or Gastrointestinal Disorders
Gerald B. Lee, MD

Adjourn

3:00 – 4:30 pm CST

Oral Abstracts – Allergy Diagnostics/Aerobiology/ Food Allergy

Moderator: Gerald B. Lee, MD

3:00 pm
Welcome and Introductions
Gerald B. Lee, MD

3:03 pm
Decoding Allergic Poly-sensitization With Machine Learning
Brian Patchett

3:18 pm
The Role of Aeroallergens in the Pathogenesis of Eosinophilic Esophagitis: Is There a Relationship?
Talal Nsouli, MD, FACAAI (HON)

3:33 pm
Specific Peanut Epitopes as a Biomarker for Desensitization During Epicutaneous Immunotherapy
David M. Fleischer, MD, FACAAI

3:48 pm
Dietary Access and Behaviors Among Food Allergic Black and White Children in the FORWARD Study
Amaziah Coleman, MD

4:03 pm
Questions and Discussion (Online Chat)

4:30 pm
Adjourn

3:00 – 4:30 pm CST

Editor’s Pick – Best Articles from Annals of Allergy, Asthma and Immunology

Moderator: John J. Oppenheimer, MD, FACAAI

This session will highlight several of the best articles published in Annals. The current Editor-in-Chief of Annals, Gailen Marshall, Jr., MD, PhD, FACAAI, and Editor-in-Chief Elect, Mitchell Grayson, MD, FACAAI, will provide insight regarding the impact and clinical application of various articles pertaining to allergy and immunology.

Speakers: Gailen D. Marshall, Jr., MD, PhD, FACAAI, and Mitchell H. Grayson, MD, FACAAI

SPECIAL PRESENTATION
There is mounting evidence that children with allergic conditions – including food allergy, eosinophilic esophagitis (EoE), and atopic dermatitis – and their families experience psychosocial stressors such as poor quality of life, stress, anxiety, depression, social challenges including bullying and low self-esteem. When examined individually, unique challenges are noted for each allergic condition due to the nature of the condition’s presentation and treatment regimen. The presenters will describe the psychological intervention services they provide and how mental health professionals are integrated into clinics that treat these populations.

Educational credit for the Advanced Practice Health Care Providers Course is only available to those who pre-registered for it.

3:00 pm  Welcome and Introductions  Jodi A. Shroba, MSN, APRN, CPNP
3:03 pm  The Clinical Role of Psychology in Food Allergy  Ashley Ramos, PhD
3:25 pm  Psychosocial Challenges in Pediatric Eosinophilic Esophagitis  Ashley Kroon Van Diest, PhD
3:50 pm  Assessing Emotional and Behavioral Health in Children and Adults With Atopic Dermatitis  Jennifer Darr, MSW, LCSW
4:15 pm  Questions and Discussion (Online Chat)
4:30 pm  Adjourn

4:30 - 5:15 pm CST  ACAAI 2020 Annual Business Meeting
All members are invited to attend. Learn about important College initiatives and help us recognize our 2020 award recipients. We’ll also welcome our new officers and regents.

5:15 - 6:15 pm CST  29th Annual FIT Bowl
Emcee: Bryan Martin, DO, FACAAI
Supported by DBV Technologies
Test your knowledge, sharpen your wits and join in the fun at this year’s virtual FIT Bowl! Watch participating teams from training programs around the country compete to answer a variety of questions posed by an expert panel. See page 13 for more information.
Sunday, November 15

**How To Implement Updates From the Latest Clinical Guidelines Into Practice**

*Moderator: Todd A. Mahr, MD, FACAAI*

This plenary will include high-yield practical information from three recently updated practice parameters: Rhinitis, Anaphylaxis and Diagnostic Testing for Peanut Allergy. Each speaker was intimately involved in the development of each guideline and can offer unmatched perspective. This is a can’t-miss session applicable to all meeting attendees.

8:00 am  Welcome and Introductions  Todd A. Mahr, MD, FACAAI
8:03 am  Practice Parameter – Rhinitis  Mark S. Dykewicz, MD, FACAAI
8:30 am  Practice Parameter – Anaphylaxis  Marcus S. Shaker, MD, FACAAI
8:55 am  Practice Parameter – Diagnostic Testing for Peanut Allergy  Matthew C. Greenhawt, MD, MBA, MSc, FACAAI
9:20 am  Questions and Discussion
9:30 am  Adjourn

**SLIT Versus SCIT – Let the Battle Begin**

*Moderators: Myron J. Zitt, MD, FACAAI, and Stanley M. Fineman, MD, MBA, FACAAI*

Presently, there are two delivery options for immunotherapy available to treat respiratory allergy. Many allergists have difficulty in determining the optimal therapy for their patients.

**Track: Immunotherapy and Diagnostics**

8:00 am  Welcome and Introductions  Myron J. Zitt, MD, FACAAI, and Stanley M. Fineman, MD, MBA, FACAAI
8:03 am  SCIT Is the Answer  David I. Bernstein, MD, FACAAI
8:30 am  SLIT Is the Answer  Peter S. Creticos, MD
8:55 am  No One Option Is Perfect – A Role for Shared Decision-making  Desiree E. Larenas-Linnemann, MD
9:20 am  Questions and Discussion
9:30 am  Adjourn

**Time Zones**

*All sessions are listed in Central Standard Time (CST). Don’t forget to convert them to your local time zone when planning your schedule!*
Separate registration required

Literature Review:
Morning Program – Part 1

Moderator: James T. Li, MD, PhD, FACAAI

To help you stay abreast of the latest clinical developments in allergy and immunology, the College will continue its highly successful literature review program. It’s a review of the most important, clinically-focused literature of our specialty published between November 2019 and October 2020, with emphasis on clinical relevance. Faculty includes allergy/immunology training program directors and specialists in practice.

The Literature Review Program is only available to those who pre-registered for it.

Welcome and Introductions
James T. Li, MD, PhD, FACAAI

Basic Immunology
Mitchell H. Grayson, MD, FACAAI

Rhinitis and Sinusitis
Anju T. Peters, MD

Update in Clinical Immunology
John M. Routes, MD, FACAAI

Adjourn

Itching to Help: Diagnosis and Management of Itch and Dermatitis in Special Populations

Moderators: Ira Finegold, MD, FACAAI, and Ellen R. Sher, MD, FACAAI

Conditions impacting the skin can change dramatically in patients with different backgrounds. This session will review special populations and how evaluation and treatment of dermatitis can be tailored based on physiologic, socioeconomic and psychosocial differences.

Track: Dermatology

8:00 am Welcome and Introductions
Ira Finegold, MD, FACAAI, and Ellen R. Sher, MD, FACAAI

8:03 am Itch and Dermatitis in the Elderly
David R. Weldon, MD, FACAAI

8:30 am Dermatitis in Skin of Color
Andrew Alexis, MD, MPH

8:55 am Occupational Dermatitis
Karin A. Pacheco, MD, MSPH

9:20 am Questions and Discussion (Online Chat)

9:30 am Adjourn
Sunday, November 15

8:00 – 9:00 am CST
Building ABAI Continuing Certification Together

Moderators: Michael R. Nelson, MD, PhD, FACAAI, and Kathleen May, MD, FACAAI

The ACAAI, ABAI and diplomates are key stakeholders in the current transformation of Allergy and Immunology Continuing Certification. This session will provide attendees with an overview of the current landscape of continuing board certification, an update of the continuous certification assessment program (CAP) and the personal progress meter. An interactive town hall will be held during this session as part of ABAI’s commitment to co-development of specialty continuing certification.

Track: Practice Management / Professional Issues

Welcome and Introductions
Michael R. Nelson, MD, PhD, FACAAI, and Kathleen May, MD, FACAAI

Provide Understanding of Continuous Assessment Program (CAP)
Michael R. Nelson, MD, PhD, FACAAI

Understand the ABMS, ABAI Vision Commission and What It Means to You
Michael R. Nelson, MD, PhD, FACAAI

Understand Use of Diplomate Progress Meter
Kathleen May, MD, FACAAI

Town Hall Q&A (Online Chat)
Michael R. Nelson, MD, PhD, FACAAI; Kathleen May, MD, FACAAI; Ted Freeman, MD, FACAAI; Rayne Harrison and Cecelia MacCormack

Adjourn

8:00 – 9:00 am CST
Oral Abstracts – Clemens von Pirquet Awardees

Moderator: Brian T. Kelly, MD, MA, FACAAI

ACAAI is pleased to present our Clemens von Pirquet Recipients for the 2020 Annual Meeting.

8:00 am Welcome and Introductions
Brian T. Kelly, MD, MA, FACAAI

8:03 am Clemens von Pirquet – 1st Place Award
Pulse Oximetry and Centile-based Vital Signs Predict Hospital Length of Stay in Pediatric Asthma Exacerbation
Jose Rojas Camayo, MD

8:18 am Clemens von Pirquet – 2nd Place Award
Clinical Impact of Reported Non-steroidal Anti-inflammatory Drug Allergies in Patients With Osteoarthritis
Lily Li, MD

8:33 am Clemens von Pirquet – 3rd Place Award
Characterizing Asthma Among Adults With Primary Antibody Deficiencies: Results From a Nationwide Patient Survey
Deepti Deshpande, MD

8:48 am Questions and Discussions (Online Chat)

9:00 am Adjourn
8:00 – 8:45 am CST

Allied Health Professionals Program

The Role of the Nurse in the Care and Management of Patients With Atopic Dermatitis

Moderator: Abby L. Allen, RN, NP

Supported by an independent educational grant from Aimmune Therapeutics

This session will discuss the diagnosis and management of atopic dermatitis. It will also discuss the role that allied health professionals play in providing emotional support, formal and systematic education and individualized practical advice that contributes to improved treatment adherence and can enhance the quality of life for patients and their families throughout the course of an often-prolonged disease.

Educational credit for the Allied Health Professionals Course is only available to those who pre-registered for it.

Welcome and Introductions
Abby L. Allen, RN, NP

The Role of the Nurse in the Care and Management of Patients With Atopic Dermatitis
Sally Schoessler, MSEd, BSN, RN, AE-C

Adjourn

10:00 – 11:30 am CST

Coding and Government Relations

Moderators: James Sublett, MD, FACAAI, and Warner W. Carr, MD, FACAAI

This session will address relevant changes, modifications and implementation of CPT and ICD-10 coding for 2021. This will be accomplished by practical case-based scenarios focused on how the change may affect the practice of allergy and clinical immunology. In addition, we’ll review the state of politics and the national perspective of medicine as seen through the eyes of the AMA. Finally, we’ll offer an update on the changing landscape on Capitol Hill as it relates to the current state of government.

Track: Practice Management / Professional Issues

10:00 am Welcome and Introductions
James L. Sublett, MD, FACAAI, and Warner W. Carr, MD, FACAAI

10:03 am Coding Update
Gary N. Gross, MD, FACAAI

10:28 am The Importance of the Physician Advocate
James M. Tracy, DO, FACAAI

10:53 am Government/Legislative Update
Bill Finerfrock, President, Capitol Associates; Consultant, Advocacy Council of ACAAI

11:20 am Questions and Discussion

11:30 am Adjourn
Caring for Patients Across Multiple Populations

Moderators: Jeremy S. Katcher, MD, FACAAI, and Jared Darveauux, MD

Supported in part by an independent educational grant from AstraZeneca

The more we learn about asthma, the more we know it is not a “one size fits all” condition. This session will review special populations and how their asthma care can be tailored based on physiologic, socioeconomic, and psychosocial differences.

Track: Asthma and Respiratory / Sleep Disorders

10:00 am Welcome and Introductions
Jeremy S. Katcher, MD, FACAAI, and Jared Darveauux, MD

10:03 am Impact of Hormones and Pregnancy on Asthma and Allergies
Jennifer Namazy, MD

10:30 am Asthma, Rhinitis and Allergic Skin Disease in Older Adults
Tolly E. Epstein, MD, MS, FACAAI

10:55 am Racial and Ethnic Disparities in Asthma and Allergic Disease
Andrea J. Apter, MD, FACAAI

11:20 am Questions and Discussion

11:30 am Adjourn

Literature Review: Morning Program – Part 2

Moderator: James T. Li, MD, PhD, FACAAI

To help you stay abreast of the latest clinical developments in allergy and immunology, the College will continue its highly successful literature review program. It’s a review of the most important, clinically-focused literature of our specialty published between November 2019 and October 2020, with emphasis on clinical relevance. Faculty includes allergy/immunology training program directors and specialists in practice.

The Literature Review Program is only available to those who pre-registered for it.

Welcome and Introductions
James T. Li, MD, PhD, FACAAI

Asthma and Lower Respiratory Diseases
James T. Li, MD, PhD, FACAAI

Update on Skin Diseases, Urticaria, Angioedema and Other Skin Disorders
Marc A. Riedl, MD, MS

Update in Pediatric Allergy
John M. Kelso, MD, FACAAI

Adjourn
Marijuana, E-cigs, Vaping, Hookah and More: How To Discuss With Patients

Moderators: Ojas P. Patel, MD, FACAAI, and Andrew Nickels, MD, FACAAI

The use of medical marijuana and its derivatives, electronic cigarettes, and alternative nicotine delivery systems is on the rise, yet the risks and health benefits remain largely unclear. Furthermore, recent literature suggests that some of the more popular routes of administration, including vaping and hookah, can have deleterious health effects. Due to a rise in use across various ages, allergy and immunology specialists need to understand how these agents are being used and incorporate discussion of them into patient visits.

Track: Population Health and Infectious Diseases / International Travel

10:00 am Welcome and Introductions
Ojas P. Patel, MD, FACAAI, and Andrew Nickels, MD, FACAAI

10:03 am Making Sense of the Different Terminology and Delivery Systems
William S. Silvers, MD, FACAAI

10:30 am Risks, Benefits and Adverse Effects: What Does the Evidence Show?
Rohit K. Katial, MD, FACAAI

10:55 am How To Effectively Discuss Use With Adolescent Patients
Kevin R. Murphy, MD, FACAAI

11:20 am Questions and Discussion (Online Chat)

11:30 am Adjourn

EAACI – Allergen Immunotherapy in 2020: Still a Valid Intervention?
Moderators: Marek Jutel, MD, PhD, and J. Allen Meadows, MD, FACAAI

The EAACI Symposium is dedicated to allergen immunotherapy as an essential tool for achieving long-term control of allergic diseases and asthma.

Track: Immunotherapy and Diagnostics

Welcome and Introductions
Marek Jutel, MD, PhD, and J. Allen Meadows, MD, FACAAI

Barriers and Facilitators in Research and Clinical Practice
Stefano del Giacco, MD, PhD

AIT for Allergic Asthma - Controversies and Solutions
Ioana O. Agache, MD, PhD

Bridging the Gap: Innovative Methodology for AIT Trials
Marek Jutel, MD, PhD

Adjourn
10:00 am Welcome and Introductions
Melanie A. Ruffner, MD, PhD

10:03 am Inner-city Asthma Telemedicine During COVID Pandemic
Kenny Kwong, MD

10:18 am Long-term Efficacy of a Video Module on Resident and Medical Student Understanding of Penicillin Allergy
Kavitha Thiagarajan, MD

10:33 am The Impact of COVID-19 and Disease Control Measures on Pediatric Food Allergy Parents/Caregivers and Patients
Christopher Warren, MD

10:48 am A Quality Improvement Project on Pediatric Resident Knowledge of Primary Immunodeficiency
Yatyng Chang, MD

11:03 am Expanding Penicillin Allergy Evaluation for Prenatal Patients
Lulu Tsao, MD

11:18 am Questions and Discussion (Online Chat)

11:30 am Adjourn

10:00 – 11:30 am CST
Allied Health Professionals Program
Let’s Work Together: Collaborative Patient Care Models in Community Allergy Practices

Moderator: Abby L. Allen, RN, NP

Supported by an independent educational grant from Aimmune Therapeutics

Food allergies and other allergic conditions can have a significant impact on quality of life, both medically and psychosocially. Therefore, a collaborative care model that includes partnering with allied healthcare professionals can result in more robust patient care. Participants will be given information on multiple allied healthcare fields, as well as the benefits, methods and logistics of partnering with these providers.

Educational credit for the Allied Health Professionals Course is only available to those who pre-registered for it.

Welcome and Introductions
Abby L. Allen, RN, NP

Let’s Work Together: Collaborative Patient Care Models in Community Allergy Practices
J. Wesley Sublett, MD, MPH, FACAAI; Raquel Durban, MS, RD, CSP, LDN; Tamara Hubbard, MA, LCPC; and Linda Herbert, PhD

Adjourn

11:35 am – 12:30 pm CST
Industry Programs
(See page 70 for details.)
LIVE RECORDED

Sunday, November 15

**Masqueraders of Common Allergic Conditions**

*Moderators: Eric Yen, MD, and Melanie A. Ruffner, MD, PhD*

Allergists/immunologists often see referrals for evaluation of patients who have a clinical history and/or laboratory results that overlap between allergies and other systemic conditions. This session will offer practical tips on how to navigate the differential diagnosis and evaluation of patients who lack clear diagnoses.

**Track:** Clinical Immunology and Autoimmune and Biologicals

1:00 pm  **Welcome and Introductions**  
Eric Yen, MD, and Melanie A. Ruffner, MD, PhD

1:03 pm  **Elevated Total IgE Levels: What Can It Mean and When To Worry?**  
Alexandra Freeman, MD

1:30 pm  **Evaluating a Patient With Elevated Peripheral Eosinophilia**  
Princess Ogbogu, MD, FACAAI

1:55 pm  **Autoimmune and Inflammatory Mimickers**  
Jennifer R. Heimall, MD

2:20 pm  **Questions and Discussion**

2:30 pm  **Adjourn**

---

**The AAAAI/ACAAI/CSACI North American Food Allergy Prevention Guidelines**

*Moderators: Susan Waserman, MD, FACAAI, and Aikaterini Anagnostou, MD, PhD, FACAAI*

In the wake of the multiple early introduction trials and a host of international guidelines and meta-analyses that have been published in the past 5 years, the three North American allergy societies have jointly developed a set of comprehensive recommendations outlining an approach to the prevention of IgE-mediated food allergy, which update the respective society recommendations that predated these new developments. This session will inform the clinician regarding the new developments and the recommended evidence-based approach that balances both cutting-edge scientific advances and practical implementation of these recommendations.

**Track:** Food & Drug Allergy and GI Disorders

1:00 pm  **Welcome and Introductions**  
Susan Waserman, MD, FACAAI, and Aikaterini Anagnostou, MD, PhD, FACAAI

1:03 pm  **What’s New? Changes and Updates in Prevention Recommendations**  
Elissa M. Abrams, MD

1:30 pm  **Policy Implications of the Updated Recommendations**  
Marcus S. Shaker, MD, MSc, FACAAI

1:55 pm  **Lessons Learned From Widespread Implementation of Prevention Guidelines**  
Kirsten Perrett, MD

2:20 pm  **Questions and Discussion**

2:30 pm  **Adjourn**
Sunday, November 15

**Literature Review: Afternoon Program – Part 1**

Moderator: David A. Khan, MD, FACAAI

To help you stay abreast of the latest clinical developments in allergy and immunology, the College will continue its highly successful literature review program. It’s a review of the most important, clinically-focused literature of our specialty published between November 2019 and October 2020, with emphasis on clinical relevance. Faculty includes allergy/immunology training program directors and specialists in practice.

*The Literature Review Program is only available to those who pre-registered for it.*

**Welcome and Introductions**

David A. Khan, MD, FACAAI

**Anaphylaxis and Stinging Insect Hypersensitivity**

Anne K. Ellis, MD, MSc, FACAAI

**Immunotherapy**

Harold S. Nelson, MD, FACAAI

**Food Allergy**

Matthew C. Greenhawt, MD, MSc, MBA, FACAAI

**Adjourn**

---

**The Influence of Social Media on Patients and Medical Decision Making**

Moderator: Brian T. Kelly, MD, MA, FACAAI

A targeted look deep down the rabbit hole of biases, conspiracies and echo chambers during the COVID-19 pandemic.

**Track:** Population Health and Infectious Diseases / International Travel

- **1:00 pm** Welcome and Introduction
  - Brian T. Kelly, MD, MA, FACAAI

- **1:03 pm** The Influence of Social Media on Patients and Medical Decision-making
  - David R. Stukus, MD, FACAAI

- **2:03 pm** Questions and Discussion (Online Chat)

- **2:30 pm** Adjourn
Sunday, November 15

**Oral Abstracts – Food Allergy**

Moderator: Aikaterini Anagnostou, MD, PhD, FACAAI

1:00 pm  Welcome and Introductions
          Aikaterini Anagnostou, MD, PhD, FACAAI

1:03 pm  Phenotypic Differences in Allergy to Multiple Foods Within a Cohort of Black and White Children
          Christopher Warren, PhD

1:18 pm  Race/Ethnicity and Socioeconomic Status Effect on Food Allergy-related Quality of Life in Children and Caregivers
          Christine Rubeiz, MD

1:33 pm  Tree Nut Graded Oral Food Challenge Outcomes in a Pediatric Tertiary Care Center
          Melissa Anderson, MD

1:48 pm  Barriers to Oral Food Challenges: A Qualitative Analysis of the Caregiver Perspective
          Natasha Correa, MD

2:03 pm  Food Allergy-related Bullying and School Policy Among Black and White Children in the FORWARD Study
          Dannielle Brown, MD

2:18 pm  Questions and Discussion (Online Chat)

2:30 pm  Adjourn

**Allied Health Professionals Program**

**Oral Challenge Update**

Moderator: Abby L. Allen, RN, NP

Supported by an independent educational grant from Aimmune Therapeutics

Oral challenges are an essential part of food allergy management. This session will review how to successfully perform oral challenges in the office and how to integrate the updated guidelines into your practice.

*Educational credit for the Allied Health Professionals Course is only available to those who pre-registered for it.*

1:00 pm  Welcome and Introductions
          Abby L. Allen, RN, NP

1:03 pm  Oral Food Challenge Update
          J. Andrew Bird, MD, FACAAI

1:25 pm  In-office Challenges: Conducting Oral Food Challenges
          Maria Crain, APRN, CPNP

1:50 pm  Oral Challenge Updates: Considerations From a Dietitian
          Raquel Durban, MS, RD, CSP, LDN

2:15 pm  Questions and Discussion (Online Chat)

2:30 pm  Adjourn
GINA Versus NHLBI Asthma Guidelines: How Do We Reconcile Differences?

Moderators: James M. Quinn, MD, FACAAI, and Anthony J. Bonitatibus, MD

The updated 2019 GINA Guidelines represent a major shift in the strategy of treating mild asthma. Though there is potential long-term benefit to the patient, there are challenges in the adoption of these guidelines. This session will review the benefits and challenges of these guidelines in the context of patient care, provider adherence, the pharmaceutical industry and regulatory (FDA) issues.

Track: Asthma and Respiratory / Sleep Disorders

3:00 pm Welcome and Introductions
James M. Quinn, MD, FACAAI, and Anthony J. Bonitatibus, MD

3:03 pm Where Do They Overlap?
Jonathan A. Bernstein, MD, FACAAI

3:30 pm Where Do They Differ?
Angela D. Hogan, MD, FACAAI

3:55 pm What Are They Both Missing?
Leonard B. Bacharier, MD, FACAAI

4:20 pm Questions and Discussion

4:30 pm Adjourn

The Challenges of Severe Conjunctival Inflammation

Moderators: Jonathan M. Rodrigues, MD, FACAAI, and Purvi S. Parikh, MD, FACAAI

Treatment of the inflamed eye can present significant challenges in the clinical setting, especially when multiple conditions may be present at the same time. Current scientific information about the pathophysiology, diagnosis and management of dry eye syndrome and allergic eye conditions will be presented. The attendees will subsequently be empowered to improve patient outcomes.

Track: Rhinitis / Sinusitis / Ocular and Anaphylaxis

3:00 pm Welcome and Introductions
Jonathan M. Rodrigues, MD, FACAAI, and Purvi S. Parikh, MD, FACAAI

3:03 pm Pathophysiology of Dry Eye Syndrome and Allergic Ocular Conditions
Merin E. Kuruvilla, MD

3:30 pm Diagnostic Evaluation of the Inflamed Eye
Guillermo Amescua, MD

3:55 pm Treatment of Dry Eye Syndrome and Allergic Ocular Conditions
Leonard Bielory, MD, FACAAI

4:20 pm Questions and Discussion

4:30 pm Adjourn
Literature Review: Afternoon Program – Part 2

Moderator: David A. Khan, MD, FACAAI

To help you stay abreast of the latest clinical developments in allergy and immunology, the College will continue its highly successful literature review program. It’s a review of the most important, clinically-focused literature of our specialty published between November 2019 and October 2020, with emphasis on clinical relevance. Faculty includes allergy/immunology training program directors and specialists in practice.

The Literature Review Program is only available to those who pre-registered for it.

Welcome and Introductions
David A. Khan, MD, FACAAI

Occupational and Environmental Allergy
Mark S. Dykewicz, MD, FACAAI

Drug Allergy
Aleena Banerji, MD

The Year’s Best Articles
David A. Khan, MD, FACAAI

Adjourn

Microbiome Across the Spectrum of Allergic Conditions

Moderators: Christina E. Ciaccio, MD, MSc, FACAAI, and Mitchell H. Grayson, MD, FACAAI

The microbiome is a hot topic and evidence surrounding its association with various allergic conditions is rapidly accumulating. This session will review the supportive evidence, practical approaches we can take now with our patients and unanswered questions that surround how the microbiome impacts common allergic conditions.

Track: Clinical Immunology and Autoimmune and Biologicals

Welcome and Introductions
Christina E. Ciaccio, MD, MSc, FACAAI, and Mitchell H. Grayson, MD, FACAAI

The Impact of the Microbiome on Atopic Dermatitis
Richard Gallo, MD

Respiratory Microbiome and Its Effect on Asthma
Christina E. Ciaccio, MD, MSc, FACAAI

Alterations in the Microbiome in Patients With Food Allergies
Carina Venter, PhD, RD

Adjourn
Hereditary Angioedema: Rising to the Challenge

Moderators: William R. Lumry, MD, FACAAI, and Amar Dixit, MD

Hereditary angioedema (HAE) remains a condition with significant morbidity. In recent years, multiple new therapeutic options have been developed, with additional ones in the pipeline. This session will compare the WAO HAE guidelines with the US HAE guidelines and differentiate between intravenous C1 inhibitor, subcutaneous C1 inhibitor and the monoclonal antibody lanadelumab. In addition, future therapeutic options for HAE will be reviewed.

Track: Dermatology

3:00 pm  Welcome and Introductions
William R. Lumry, MD, FACAAI, and Amar Dixit, MD

3:03 pm  Comparing WAO Hereditary Angioedema and US Hereditary Angioedema Guidelines
Timothy J. Craig, DO, FACAAI

3:30 pm  How To Choose From the Current Therapies
Aleena Banerji, MD

3:55 pm  What Does the Future Hold for Hereditary Angioedema Therapy?
Marc A. Riedl, MD, MS

4:20 pm  Questions and Discussion (Online Chat)

4:30 pm  Adjourn

---

Food Allergy Mimickers: Non-IgE Food Intolerances

Moderator: Abby L. Allen, RN, NP

Supported by an independent educational grant from Aimmune Therapeutics

This session will review how to differentiate IgE from non-IgE food conditions with appropriate testing. Once a diagnosis has been formulated, this session will review management of the condition, including the implementation of nutritional recommendations.

Educational credit for the Allied Health Professionals Course is only available to those who pre-registered for it.

3:00 pm  Welcome and Introductions
Abby L. Allen, RN, NP

3:03 pm  Food Allergy Mimickers: Non-IgE Food Intolerances
Ashlee Law, PA-C

3:25 pm  Food Allergy Mimickers: A Dietitian’s Vantage Point
Raquel Durban, MS, RD, CSP, LDN

3:50 pm  Food Allergy Mimickers: Non-IgE Food Intolerances
Abby L. Allen, RN, NP

4:15 pm  Questions and Discussion (Online Chat)

4:30 pm  Adjourn

---

4:30 pm CST
Annual Scientific Meeting Adjourns

Thank you for joining us! Be safe.
Electronic posters are a vital part of your meeting experience. The posters and presentation schedule are searchable and accessible 24/7 online at college.acaai.org/eposters.

**New for 2020!** E-posters will be accompanied by an audio/video presentation delivered by the presenting author.

Two categories of e-posters are included. **Scientific Research** e-posters feature new studies and research in the field of allergy/immunology. **Medically Challenging Case** e-posters highlight the management of novel or very uncommon diseases, the unusual presentation of a disease or something unusual masquerading as common.

E-posters will be available for viewing online beginning November 13 and remain available through August 2021.
Industry Programs – Friday
Available in the Auditorium of the Virtual Annual Meeting

These are non-CME offerings. NOT FOR CREDIT

Friday, November 13 • 9:35 – 10:00 am

**Type 2 Inflammation in Asthma**
*Presented by: Todd Mahr, MD*
During this case-based presentation, an expert will review the role of Type 2 inflammation in asthma.
*Supported by Sanofi Genzyme and Regeneron*

Friday, November 13 • 11:35 am – 12:30 pm

**PALFORZIA® (Peanut (Arachis hypogaea) Allergen Powder-dnfp) From Evidence to Practice: The First FDA-Approved Treatment for Peanut Allergy**
*Presented by: Dareen Siri, MD and Ananth Thyagarajan, MD*
Peanut allergy can significantly impact patients’ lives. With PALFORZIA now available, you can provide your patients with the first FDA-approved treatment for peanut allergy. Please join Dareen Siri, MD and Ananth Thyagarajan, MD as they review the clinical safety and efficacy of PALFORZIA and share their treatment experience.
*Supported by Aimmune Therapeutics*

**Investigating the Role of Eosinophils in Health, Airway Disease, and Hypereosinophilic Disorders**
*Presented by: Charlene Prazma, PhD, Chair; Steven J. Ackerman, PhD; Jonathan Corren, MD; and Princess Ogbogu, MD*
Eosinophils are well recognized as having important roles in immune-mediated disorders. Our program will review the immunomodulatory role of eosinophils in health and disease and their involvement in severe asthma (and potential co-morbidities) and hypereosinophilic disorders. The importance of biomarkers in the evaluation of eosinophilic disorders will also be highlighted.
*Supported by GSK*

**Rediscover Prevention: Proven Efficacy for Patients With HAE**
*Presented by: Marc Riedl, MD and Andrea, Patient Ambassador*
Rediscover prevention in this dynamic program featuring data that shows what attack prevention can mean for your patients with HAE. Expert faculty will guide you through clinical data, including our new open-label extension study data, and a patient ambassador will bring the data to life by sharing her individual treatment experience.
*Supported by Takeda Pharmaceutical Company Limited*
Industry Programs – Friday
Available in the Auditorium of the Virtual Annual Meeting

These are non-CME offerings.

Friday, November 13 • 2:35 – 3:00 pm

**Understanding Nasal Polyposis**
*Presented by: Tara F. Carr, MD*
A non-CME, disease state presentation focusing on nasal polyposis. Topics include: characteristics of nasal polyps, pathophysiology, common comorbid conditions, the role of type 2 inflammation in nasal polyposis, and the importance of an integrated multidisciplinary approach for optimal management.

*Supported by Novartis Pharmaceuticals Corporation*

Friday, November 13 • 5:30 – 6:30 pm

**Type 2 Inflammation**
*Presented by: Ujwala Kaza, MD*
During this case-based presentation, an expert will review the role of Type 2 inflammation in asthma, chronic rhinosinusitis with nasal polyposis, and atopic dermatitis.

*Supported by Sanofi Genzyme and Regeneron*

Friday, November 13 • 5:30 – 6:30 pm continues on next page.
Industry Programs – Friday
Available in the Auditorium of the Virtual Annual Meeting

These are non-CME offerings.

Friday, November 13 • 5:30 – 6:30 pm

See EoE: A Closer Look at Diagnosing and Managing Eosinophilic Esophagitis
Presented by: Jonathan Spergel, MD, PhD and Ikuo Hirano, MD
Join our multidisciplinary speakers as they walk us through their perspectives of the most recent diagnostic and management guidelines for Eosinophilic Esophagitis. Together they will define EoE, describe various manifestations of chronic esophageal inflammation, and explore diagnostic challenges and management approaches in the context of guideline recommendations.

Supported by Takeda Pharmaceuticals U.S.A., Inc.

Industry Programs – Saturday

Saturday, November 14 • 7:00 – 7:55 am

Systemic Mastocytosis: An Allergist/Immunologist Perspective on Diagnosis and Treatment
Presented by: Mariana Castells, MD, PhD

Supported by Blueprint Medicines

Saturday, November 14 • 9:35 – 10:00 am

Managing Food Allergy During the COVID-19 Pandemic and Implications for the Future
Presented by: Matthew Greenhawt, MD
The COVID-19 pandemic has revealed the importance of flexible approaches to caring for food-allergic patients, with potential implications for future treatment preferences. This symposium will include a discussion of the recent expert panel consensus document to guide decision-making in the allergy/immunology clinic, with a focus on food allergy care.

Supported by DBV Technologies

Saturday, November 14 at 9:35 - 10:00 am continues on next page.
Understanding the Needs of Infants and Toddlers With Life-Threatening Allergies

Presented by: Ruchi Gupta, MD and Todd Mahr, MD

A discussion about the rising rates of anaphylaxis and the role providers play to help reduce the risk that a child will develop certain food allergies by identifying high-risk patients and educating caregivers on the early introduction of allergens. Dr. Gupta and Dr. Mahr are paid advisors for kaléo, Inc.

Supported by kaléo

Targeting a Common Contributor to Severe Asthma

Presented by: Katharine Woessner, MD

You are cordially invited to view a pre-recorded program to learn about the clinical impact of a targeted biologic treatment option on exacerbations, lung function, and reducing oral corticosteroids in patients with severe eosinophilic asthma. Listen to an expert to explore its clinical efficacy, mechanism of action, and safety profile data.

Supported by AstraZeneca

A Treatment Option for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months and Older

Presented by: Adelaide A. Hebert, MD

Join us for an interactive presentation on a steroid-free topical therapy for the treatment of mild-to-moderate atopic dermatitis. Expert faculty will guide the audience through an in-depth look into the product and answer questions to help attendees gain a better understanding of this treatment option.

Supported by Pfizer, Inc.
Industry Programs – Saturday
Available in the Auditorium of the Virtual Annual Meeting

These are non-CME offerings.

Saturday, November 14 • 11:35 am – 12:30 pm

The Role of Digitally Connected Inhalers: An Introduction to Digihaler® Technology
Presented by: Greg Bensch, MD

Please join us on November 14th at 11:35 am as Greg Bensch, MD presents Digihaler® Technology. Learn about the role of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder, ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder and AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder in clinical practice.

Supported by Teva Pharmaceuticals, Inc.

Saturday, November 14 • 2:35 – 3:00 pm

Current Understanding of Hypereosinophilic Syndrome (HES): A Rare Inflammatory Eosinophilic Disease
Presented by: David Bernstein, MD

Hypereosinophilic syndrome (HES) is a rare and debilitating multi-system disorder characterized by elevated eosinophil levels in blood and/or tissues with organ damage/dysfunction that occurs without evidence of secondary causes of hypereosinophilia. Multiple organ involvement results in highly variable clinical manifestations. This brief presentation will provide a summary of current understanding.

Supported by GSK
Disrupting Decades of Unmet Need: Targeting Uncontrolled Asthma & SABA Reliance With PRECISION

Presented by: Bradley Chipps, MD; Miguel Lanz, MD; and Kevin Murphy, MD

Join us to discuss real-world evidence updates on the relationships of asthma control, patient behaviors and SABA reliance as we focus on the unmet need in asthma patients who may be at risk for exacerbations. Learn how PRECISION may help improve the identification and management of patients with uncontrolled asthma.

Supported by AstraZeneca

The Journey Towards Controlled Asthma: Shifting the Treatment Paradigm

Presented by: John Oppenheimer, MD and Angela Hogan, MD

Uncontrolled asthma continues to burden patients, care teams, and healthcare systems. Medical experts will provide insight into the challenges of coping with uncontrolled asthma, review the current treatment paradigms, and identify ways to customize management of uncontrolled asthma by pairing the right medications with the right patients.

Supported by GSK

Keeping the Cat: A Transformational Approach to Reducing Fel d 1 Through the Cat’s Diet

Presented by: Ebenezer Satyaraj, PhD

This presentation provides an in-depth look at a proven innovation to neutralize Fel d 1, the major cat allergen, at its source. As part of a comprehensive allergen management program, this approach is safe for the cat and helps keep the cat in the home.

Supported by Purina Institute
Sunday, November 15 • 11:35 am – 12:30 pm

**Eosinophilic Immune Dysfunction**  
*Presented by: Rohit Katial, MD*

Join us for a presentation that will provide an overview of eosinophilic immune dysfunction, which can be characterized as the dysregulation of biological mechanisms involved with eosinophil recruitment and activation that is seen across a range of diseases.  

**Supported by AstraZeneca**

---

**Clinical and Real-World Evidence for Using a Biologic to Treat Severe Eosinophilic Asthma**  
*Presented by: Jacqueline Eghrari-Sabet, MD*

This expert-led event will include a review and discussion of clinical and real-world data evaluating a biologic treatment to help reduce exacerbations and maintenance OCS use, as well as long-term clinical efficacy and safety data associated with the product.  

**Supported by GSK**

---

**Deepening Our Understanding: Cytokine Signaling and the JAK/STAT Pathway in Atopic Dermatitis**  
*Presented by: Lee S. Clore Jr, MD*

During this presentation, Dr. Clore will review the disease state and burden of atopic dermatitis (AD), discuss the integral components in the pathophysiology of AD, and describe the role of the JAK/STAT pathway in AD.  

**Supported by Pfizer, Inc.**
The virtual exhibit hall opens at 9:30 am CST on Friday, November 13. The College appreciates the support of its exhibitors and urges all attendees to visit over 40 virtual booths in the exhibit hall. Chat with industry representatives during meeting hours, or drop in anytime to view exhibits. Plus, collect tokens for the Leaderboard Contest to qualify to win great prizes!

Also visit the College and Foundation booths to learn about resources and opportunities to engage.

Exhibits will remain viewable through February 6, 2021 following the Annual Meeting.

ADMA Biologics
465 New Jersey 17 S
Ramsey, NJ 07446
Phone: (201) 478-5552
Website: admabiologics.com
Contact Name: Michael Least
Contact Email: mleast@admabio.com

ADMA Biologics is an end-to-end commercial biopharmaceutical company committed to manufacturing, marketing and developing specialty plasma-derived products for the prevention and treatment of infectious diseases in the immune compromised and other patients at risk for infection. Our devotion to these underserved populations fuels us, and our hands-on approach to production and development sets us apart.

Gold Partner

Aimmune Therapeutics
8000 Marina Blvd
3rd Floor
Brisbane, CA 94005
Phone: (408) 886-8984
Website: www.aimmune.com
Contact Name: Jennifer Kirchner
Contact Email: jkirchner@aimmune.com

Aimmune Therapeutics, Inc. is a biopharmaceutical company developing and commercializing treatments for patients with food allergies. Aimmune was formed by leading food allergy stakeholders who concluded that a standardized oral immunotherapy approach was needed and that associated therapies needed to be developed. To deliver on that purpose, Aimmune developed the Characterized Oral Desensitization ImmunoTherapy (CODIT®) approach, which is intended to mitigate allergic reactions from accidental exposure to food allergens. Aimmune is the first company to have an FDA-approved treatment for any food allergy and is applying the CODIT approach to investigate additional food allergy therapies. Please visit www.aimmune.com.

Silver Partner

ALK-Abelló, Inc
1700 Royston Ln
Round Rock, TX 78664
Phone: (908) 842-8359
Website: www.alk.net/us
Contact Name: Paul Ulrich
Contact Email: paul.ulrich@alk.net

The world leader in allergy immunotherapy (AIT), ALK is devoted to improving the quality of life for people with allergies by offering more convenient methods of administration, and thereby expanding the overall use of AIT to more patients. We are committed to broadening our presence in allergy care and will continue to innovate, develop and market new solutions beyond AIT, that bring us closer to allergic patients. Our goal is to build an effective future growth platform to engage with allergic patients and connect them with allergy specialists earlier in the disease progression.
The College’s Foundation, now named the Allergists’ Foundation, has taken a new direction in its programming to focus more keenly on the needs of practicing community allergists. Stop by the Foundation booth in the virtual exhibit hall to learn more and get information on how you can apply for a grant and/or support these efforts.

Altus Biologics
11233 Shadowcreek Pkwy
Suite 303
Pearland, TX 77584
Phone: (845) 518-4382
Website: www.altusbiologics.com/blog
Contact Name: Jeraldin Fandino
Contact Email: jfandino@altusbiologics.com

Altus Biologics is a biologics management organization. We partner with physicians across multiple specialties to provide comprehensive, in-office infusion and subcutaneous injection services, allowing the physician to have full oversight of patient treatment. At Altus Biologics, we are committed to improving access, quality of care and affordability for all patients. We stand by our motto, “Treat each patient like family.”

Amgen/AstraZeneca
1800 Concord Pike
Wilmington, DE 19850-5437
Phone: (302) 885-2677
Website: www.astrazeneca-us.com
Contact Name: Brendan McEvoy
Contact Email: USMediateam@astrazeneca.com

Amgen and AstraZeneca have partnered together to bring new and innovative science to an area where there remains a significant unmet need. The partnership leverages both companies’ respective capabilities including AstraZeneca’s extensive respiratory experience and Amgen’s deep history in inflammatory diseases and bringing novel therapies to patients. Visit our Virtual Booth Experience to investigate the connection between TSLP, the epithelium and severe asthma inflammation.

AstraZeneca Pharmaceuticals, LP
1800 Concord Pike
Wilmington, DE 19850-5437
Phone: (302) 885-2677
Website: www.astrazeneca-us.com
Contact Name: Brendan McEvoy
Contact Email: USMediateam@astrazeneca.com

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – oncology, cardiovascular & metabolic diseases and respiratory. The company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
BioCryst Pharmaceuticals, Inc.
4505 Emperor Blvd
Suite 200
Durham, NC 27703
Phone: (919) 270-1275
Website: www.biocryst.com
Contact Name: Kavita Aggarwal
Contact Email: KAggarwal@biocryst.com

BioCryst is a biotech company headquartered in Durham, North Carolina with a Discovery Center of Excellence in Birmingham, Alabama. We discover novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.

At BioCryst, we are committed to delivering extraordinary medicines that empower patients to live ordinary lives. We are passionate about developing and advancing novel medicines with a focus on oral therapies for people with rare and serious diseases to help them take part in the everyday activities they enjoy.

BioCryst Pharmaceuticals 2
4505 Emperor Blvd
Suite 200
Durham, NC 27703
Phone: (717) 968-1514
Website: www.biocryst.com
Contact Name: Danielle Potteiger
Contact Email: dpotteiger@biocryst.com

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.

BioCryst has several ongoing development programs, including berotralstat (BCX7353), an oral treatment for hereditary angioedema; BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; galidesivir, a potential treatment for COVID-19, Marburg virus disease and Yellow Fever; and BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst’s first approved product.

Blueprint Medicines
45 Sidney St
Cambridge, MA 02139
Phone: (203) 376-1008
Website: www.blueprintmedicines.com
Contact Name: Lisa Young
Contact Email: lyoung@blueprintmedicines.com

Blueprint Medicines is a precision therapy company striving to improve human health. With a focus on genomically-defined cancers, rare diseases and cancer immunotherapy, we are developing transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease. Our uniquely targeted, scalable approach empowers the rapid design and development of new treatments and increases the likelihood of clinical success. We have two FDA-approved precision therapies and are currently advancing multiple investigational medicines in clinical development, along with a number of research programs.

CSL Behring
1020 First Ave
King Of Prussia, PA 19406
Phone: (610) 878-4682
Website: https://www.cslbehring.com
Contact Name: Sophia Yu

CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We meet patients’ needs using the latest technologies to develop and deliver innovative therapies. The company offers a broad range of products in the industry for treating coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease and chronic inflammatory demyelinating polyneuropathy (CIDP). CSL Behring’s products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn.

For more information visit www.cslbehring.com and follow us on Twitter @CSLBehring.
Exhibits

College Booth
85 W Algonquin Rd
Suite 550
Arlington Heights, IL 60005
Phone: (847) 725-2285
Website: college.acaai.org
Contact Name: Gina Steiner
Contact Email: ginasteiner@acaai.org

Visit the College booth to find out how the College provides the support you need. Get connected and learn more about ongoing College programs, resources, advocacy and more.

DBV Technologies
25 Deforest Ave
Summit, NJ 07901
Website: www.dbv-technologies.com

DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY.

Gold Partner

Emocha Mobile Health Inc.
916 N Charles St
2nd Floor, Suite 200
Baltimore, MD 21201
Phone: (410) 864-8587
Website: www.emocha.com
Contact Name: Amy Cummings
Contact Email: acummings@emocha.com

Emocha is the first comprehensive digital medication adherence program, using asynchronous video check-ins and scalable human engagement to help patients with asthma, tuberculosis, diabetes and transplant recipients radically improve medication adherence. Emocha remotely engages and supports patients with asthma while helping them improve non-adherence and inhaler technique, resulting in better quality of life, improved clinical metrics and decreased hospital utilization. Emocha's platform is used by health departments, hospitals and managed care organizations, with more than 120 customers across the globe serving over 50,000 patients.

Food Allergy & Anaphylaxis Connection Team (FAACT)
PO Box 511
West Chester, OH 45071
Phone: (815) 276-3015
Website: www.FoodAllergyAwareness.org
Contact Name: Eleanor Garrow-Holding
Contact Email: eleanor.garrow@foodallergyawareness.org

FAACT's mission is to educate, advocate and raise awareness for all individuals and families affected by food allergies and life-threatening anaphylaxis. FAACT is also your voice for food allergy awareness. Whether it’s keeping children safe at school, parents knowing their rights, responding to food allergy bullying, reading labels, dealing with workplace issues, traveling or dining out with the family, this website has the facts you need to manage food allergies and stay healthy. FAACT is here to support you in managing your food allergies - today, tomorrow and into the future.

Elsevier
1600 John F Kennedy Blvd
Suite 1600
Philadelphia, PA 19103
Phone: (949) 929-4717
Website: www.us.elsevierhealth.com
Contact Name: Ryan Woodford
Contact Email: r.woodford@elsevier.com

Elsevier is a world leader in medical publishing and a provider of information solutions that enhance the performance of science, health and technology professionals, empowering them to make better decisions and deliver better care.
Fresenius Kabi USA LLC
Three Corporate Drive
Lake Zurich, IL 60047
Phone: (847) 550-5027
Website: www.fresenius-kabi.com/us
Contact Name: Melissa Denton
Contact Email: melissa.denton@fresenius-kabi.com

Fresenius Kabi is a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Our products are used to help care for critically and chronically ill patients.

The people of Fresenius Kabi are driven by a common purpose to put lifesaving medicines and technologies in the hands of people who care for patients and to find answers to the challenges they face.

Gold Partner

Genentech
1 DNA Way
South San Francisco, CA 94080
Phone: (650) 225-8230
Website: www.gene.com
Contact Name: Antony Rothwell
Contact Email: rothwell.antony@gene.com

Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for more than 40 years.

Novartis Pharmaceuticals is dedicated to discovering, developing, manufacturing and marketing prescription drugs that help meet our customers’ medical needs and improve their quality of life. Please visit the Novartis exhibit where our sales representatives will be available to discuss our products.

Gold Partner

GlaxoSmithKline
Five Moore Dr
Research Triangle Park, NC 27709-3398
Phone: (888) 825-5249
Website: www.gsk.com
Contact Name: Sudha Karthigeyan
Contact Email: sudharshanaa.x.karthigeyan@gsk.com

Science-led global healthcare company with a mission to help people do more, feel better, live longer. We research, manufacture and make available a broad range of medicines, vaccines and consumer healthcare products. Visit our exhibit for information about our products and resources.

Gold Partner

Grifols USA, LLC.
2410 Lillyvale Ave
GUSA
Los Angeles, CA 90032
Phone: (323) 227-7630
Website: www.grifols.com/en/home
Contact Name: Glorianna Bartolo
Contact Email: glorianna.bartolo@grifols.com

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions - Bioscience, Diagnostic, Hospital and Bio Supplies - develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion.
Strength. Balance. Consistency. With nearly 100 years of leadership in research, extract production and immunotherapy products, doctors around the world choose HollisterStier Allergy. Our promise has always been to provide quality products, services and resources to physicians and allergy patients, and we remain committed to those ideals today. Our complete line of high quality products – including phenol-free extracts – and testing supplies, allows physicians to provide patients with the best possible care. Allergy experts since 1921. Commitment since day one.

kaléo
111 Virginia St
Suite 300
Richmond, VA 23219
Website: www.kaleo.com
Contact Name: Jennifer Norman
Contact Email: jennifer.norman@kaleo.com

kaléo is a pharmaceutical company dedicated to building innovative solutions that can help empower patients with certain serious, life-threatening medical conditions and their caregivers. kaléo products combine established drugs with innovative delivery platforms, with the goal of achieving safety, efficacy and cost effectiveness. Please visit us at our virtual AUVI-Q booth for more information.

Lincoln Diagnostics is displaying state-of-the-art, safety-engineered skin testing devices that meet all current OSHA requirements. Our products include Multi-Test® PC (Pain Control), UniTest® PC (Pain Control), Multi-Test® II, Multi-Test®, Duotip-Test® II and Duotip-Test®. Please visit our exhibit to learn about the economic value of using Lincoln’s devices and why they are the most widely used and most extensively published-on devices available.

The mission of Med Learning Group is to design educational activities for healthcare practitioners that increase competence, change behavior and optimize patient care. The focus of our education is to create innovative and interactive educational programs designed with scientific rigor, fair balance and evidence-based content.
Gold Partner

Merck & Co., Inc.
2000 Galloping Hill Rd
Kenilworth, NJ 07033
Phone: (908) 740-4000
Website: www.merck.com
Contact Name: Nadine Curtin

For more than a century, Merck has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Today, Merck continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.

ModuleMD, LLC
8359 Office Park Dr
Grand Blanc, MI 48439
Phone: (248) 434-0444
Website: www.modulemd.com
Contact Name: Miranda Moore
Contact Email: miranda.moore@modulemd.com

ModuleMD enhances the clinical, operational and financial performance of allergy practices. The ModuleMD WISE™ software suite streamlines practice processes with an integrated ONC-Certified EHR, skin testing, immunotherapy, practice management, revenue management, e-prescribe, telemedicine, appointment reminder, parking lot check-in and patient engagement software. When you select ModuleMD WISE™ for your practice, you receive more than just a product or a service; you have a dedicated partner with an interest in the success of your practice. In addition to technology, ModuleMD offers comprehensive billing and revenue management services. Providing solutions...not just software. Contact us for a demo today: info@modulemd.com

Nestlé Purina PetCare Company
1 Checkerboard Square
1C
Saint Louis, MO 63164
Phone: (314) 982-3363
Website: www.purinainstitute.com
Contact Name: Celia Suzuki
Contact Email: celia.suzuki@rd.nestle.com

Nestlé Purina PetCare is one of the world’s leading pet food companies, dedicated to promoting the bond between people and their pets. For over a decade, Purina scientists have been investigating a novel approach that can transform the management of cat allergies. The research has led to a discovery that neutralizes the major cat allergen, Fel d 1, at its source in cats’ saliva before entering the environment. Pro Plan LiveClear, the first and only cat food proven to reduce allergens in cat hair, can be integrated into current care pathways for cat allergies.

Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936-1080
Phone: (862) 223-1408
Website: www.novartis.com
Contact Name: MaryBeth McAlister
Contact Email: marybeth.mcalister@novartis.com

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 105,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.
OptiNose, Inc.
1020 Stony Hill Rd
Suite 300
Yardley, PA 19067
Phone: (267) 364-3500
Website: www.optinose.com
Contact Name: Kristen Miller
Contact Email: kristen.miller@optinose.com

Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. Optinose has offices in the U.S., the U.K. and Norway. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.

Perrigo Company plc.
490 Eastern Ave
Allegan, MI 49010
Phone: (434) 297-1148
Website: www.perrigopedia.com
Contact Name: Lindley Stakem
Contact Email: lindley.stakem@perrigo.com

For over 20 years, Perrigo has been the trusted maker of store brand infant formulas sold in the U.S., providing high quality, complete infant nutrition that meets required FDA standards at more affordable prices. To learn more, explore our full product portfolio and find a retailer near you, visit www.PerrigoPediatrics.com

Pfizer Inc.: Breakthroughs that change patients’ lives
235 East 42nd St
New York, NY 10017
Phone: (610) 506-5496
Website: www.pfizer.com
Contact Name: Gail Griffith
Contact Email: gail.griffith@pfizer.com

Pfizer Inc.: Breakthroughs that change patients’ lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Pharming Healthcare, Inc.
685 Route 202/206
Suite 202
Bridgewater, NJ 08807
Phone: (201) 675-0533
Website: www.pharming.com
Contact Name: Lauren Arce
Contact Email: lauren.arce@prihcs.com

Pharming Healthcare, Inc. is dedicated to providing life-changing solutions to patients. Pharming is currently involved in the marketing and development of drugs for the treatment of hereditary angioedema.

Sanofi Genzyme & Regeneron
777 Old Saw Mill River Rd
Tarrytown, NY 10591
Phone: (914) 847-7000
Website: www.regeneron.com / www.sanofigenzyme.com
Contact Name: Medical Information
Contact Email: medical.information@regeneron.com

Regeneron Pharmaceuticals is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. Since 2007, Sanofi & Regeneron have collaborated to develop & commercialize fully human monoclonal antibodies utilizing proprietary technologies.
SpoonfulOne was developed by globally recognized pediatric allergist, Dr. Kari Nadeau. SpoonfulOne is a revolutionary, science-backed line of nutritional products for infants and toddlers that help stop a childhood food allergy before it starts. Unlike other products on the market that only cover peanut, milk or eggs, each serving includes safe, gentle amounts of the 16 foods responsible for over 90% of food allergies. SpoonfulOne is powered by global landmark research and is backed by multiple proprietary studies. Learn more about SpoonfulOne at www.spoonfulone.com.

Stallergenes Greer
639 Nuway Circle NE
Lenoir, NC 28645
Phone: (828) 759-7844
Website: www.stagrallergy.com
Contact Name: William Mahoney
Contact Email: william.mahoney@stallergenesgreer.com

Headquartered in North Carolina, Stallergenes Greer’s business in the United States is part of a leading global biopharmaceutical company specializing in the development and commercialization of allergy immunotherapy (AIT) products and services for use in the diagnosis and treatment of allergies.

**Gold Partner**

Takeda
300 Shire Way
Lexington, MA 02421
Phone: (781) 482-6579
Website: www.takeda.com
Contact Name: Dawn Rafferty
Contact Email: dawn.rafferty@takeda.com

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing better health and a brighter future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: oncology, gastroenterology (GI), neuroscience and rare diseases. We also make targeted R&D investments in plasma-derived therapies and vaccines. www.takeda.com

**Silver Partner**

Teva Pharmaceuticals
400 Interpace Pkwy
Parsippany, NJ 07054
Phone: (570) 294-7973
Website: www.tevausa.com
Contact Name: Brian Eckley
Contact Email: brian.eckley@tevapharm.com

Teva Pharmaceuticals is a global leader in generic medicines and biopharmaceuticals. Building on more than a century-old legacy, Teva delivers high-quality products to patients in nearly every therapeutic area, has an established presence in generics, specialty, OTC and API, a fully integrated R&D function, strong operational base and global infrastructure and scale.
The American Board of Allergy & Immunology (ABAI)
1835 Market St
Suite 1210
Philadelphia, PA 19103
Phone: (215) 592-9466
Website: www.abai.org
Contact Name: Gina Capozzoli
Contact Email: gcapozzoli@abai.org

The ABAI was established in 1971 as a conjoint board of the ABIM and ABP. The internal medicine subspecialty existed from 1936-1971 and the pediatric subspecialty existed from 1944-1971. The ABAI is committed to working closely with its parent boards to maintain the highest educational and clinical standards in the specialty of allergy/immunology.

Vitalograph, Inc.
13310 W 99th St
Lenexa, KS 66215
Phone: (913) 730-3228
Website: www.vitalograph.com
Contact Name: Mark Russell
Contact Email: mark.russell@vitalograph.com

Vitalograph is a global leader of respiratory diagnostics. Our products and services are chosen by medical professionals in healthcare, occupational health, telemedicine programs and for clinical trials. We manufacture and supply high quality, accurate and reliable spirometers and respiratory medical devices which aid the detection, diagnosis, and control of respiratory conditions. We have also delivered successful clinical trials for many of the world’s leading pharmaceutical companies, biotech, and contract research organizations. Visit our corporate website: www.vitalograph.com or call 1-800-255-6626.

World Allergy Organization (WAO)
555 E Wells St
Suite 1100
Milwaukee, WI 53202
Phone: (414) 276-1791
Website: www.worldallergy.org
Contact Name: Angela Burant
Contact Email: aburant@worldallergy.org

The World Allergy Organization (WAO) is an international umbrella organization whose members consist of 103 regional and national allergology and clinical immunology societies from around the world. By collaborating with member societies, WAO provides direct educational outreach programs, symposia and lectureships to members in nearly 100 countries around the globe.
American College of Allergy, Asthma & Immunology

Call for Session Proposals

2021 ANNUAL SCIENTIFIC MEETING

The College is accepting proposals for Educational Sessions and Hands-On Workshops that echo the theme of the 2021 Annual Scientific Meeting, and:

- Reflect clinical innovation and cutting-edge research
- Convey best practices
- Present evidence-based medicine
- Stimulate discussion and challenge mindsets

Deadline for submission is: December 6, 2020

college.acaai.org/21proposals

#ACAAI21
Thank you to the 2020 ACAAI Corporate Council Members

BENEFACCTOR MEMBERSHIP

GSK

Phaming

Genentech

A Member of the Roche Group

SANOFI GENZYME

REGENERON

Takeda

PATRON MEMBERSHIP

Aimmune Therapeutics

ALK

AMGEN

kaleo

Novartis | Reimagining Medicine

Pfizer

Stallergenes Greer